<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-6171 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-6171</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-6171</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-123.html">extraction-schema-123</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <p><strong>Paper ID:</strong> paper-252611174</p>
                <p><strong>Paper Title:</strong> The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</p>
                <p><strong>Paper Abstract:</strong> Primary care professionals play a critical role in the care of their patients. In clinical practice, early detection and diagnosis of Mild Cognitive Impairment, Alzheimer's disease and related dementia are often missed or delayed. Disclosure of diagnosis is not timely or not revealed. Though the methods that could improve early detection and diagnosis have remained the same over the decades with little change, they provide opportunities for early intervention, treatment and improvement in patient care. Emerging research suggests that though the disease process begins years prior to the clinical diagnosis, the healthcare system and health care professionals remain distant and reluctant to provide the service of annual cognitive assessment, which has been recommended by the Medicare program for older adults aged 65 years and older. Findings support that Alzheimer's disease and related cognitive impairments have gone under detected, underdiagnosed and undertreated. This article seeks to provide valuable and equitable information in the form of a clinician's guide for removing the barriers to early detection and diagnosis of cognitive impairments and offers an unprecedented opportunity to improve the clinical outcomes and care of older adults with various levels of cognitive decline, including mild cognitive impairment, Alzheimer's disease, and related dementias. This article provides information on understanding and addressing the challenges faced by health care professionals, including primary care clinicians; removing the barriers to cognitive assessments; educating this professional group on the importance of brain health, early detection, and diagnosis for their older adult patients; and providing these professionals with the ability to transfer their knowledge into more defined care planning. Until cognitive screening has been fully accepted and implemented for the optimal the care of older adults, health-related efforts should include the promotion and education of brain health, early detection, and diagnosis in the education of health care providers.</p>
                <p><strong>Cost:</strong> 0.02</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e6171.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e6171.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Age</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Advanced age</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Chronological aging identified in the paper as the leading risk factor for Alzheimer's disease; risk rises with increasing age.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>age</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Increasing chronological age is the primary risk factor for Alzheimer's disease; age-related biological changes increase vulnerability to neurodegenerative processes.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Cited as 'age is the leading risk factor' referencing the National Institute on Aging and general epidemiologic consensus (paper cites NIA fact sheet and Alzheimer's Association summaries).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Narrative review / guideline-style review</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper notes age is a non-modifiable risk factor; does not provide quantitative risk estimates or age cutoffs beyond referencing standard epidemiology.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e6171.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Family history / Genetics</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Family history and genetic predisposition</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Family history/genetic predisposition is listed among risk factors for dementia/Alzheimer's disease in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>genetic</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Heritable genetic factors and family history increase risk of Alzheimer's disease through inherited variants that affect amyloid, tau, or other pathways (paper lists family history as a risk factor but does not elaborate mechanisms).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Listed among common risk factors; supported by cited background references (e.g., NIA and Alzheimer's Association materials referenced in paper).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Narrative review / literature summary</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper does not detail which genes or quantify risk; genetic risk is presented qualitatively only.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e6171.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Depression</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Depression (affective disorder)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Depression is listed both as a possible reversible contributor to cognitive impairment and as an underrecognized target for dementia prevention.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>psychiatric / modifiable risk</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Depressive symptoms and major depression in midlife or later life are associated with increased risk of cognitive decline and dementia; may act via behavioral, vascular, inflammatory, or neuroendocrine mechanisms (paper notes depression as both a reversible cause and preventive target).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper cites literature noting depression as an underrecognized prevention target (references e.g., Dafsari & Jessen 2020) and lists depression among causes to assess and treat as part of reversible contributors.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Narrative review; cites relevant clinical reviews</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper does not provide causal proof or effect sizes; frames depression as potentially remediable contributor and target for prevention rather than proven causal pathology.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e6171.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Traumatic Brain Injury</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Traumatic brain injury (TBI) / head injury</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Head injuries are listed as associated with temporary or long-lasting cognitive impairment and as a risk factor for later dementia.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>environmental / injury</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>TBI can damage brain tissue and initiate processes that cause cognitive decline; repeated or severe head trauma can lead to chronic neurodegeneration.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper lists head injuries among causes of cognitive impairment and notes association with longer-lasting impairment; draws on general literature linking TBI with later cognitive problems.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Narrative review / summary of causes</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>No quantitative risk estimates provided; paper treats TBI as one of several risk contributors without detailing dose-response or moderating factors.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e6171.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Vascular / Stroke</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Vascular disease and stroke (cerebral small vessel disease)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Vascular injury, stroke and cerebral small vessel disease are listed as causes of cognitive impairment and contributors to mixed dementia.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>vascular</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Impaired blood flow, strokes, and small vessel disease produce neuronal injury and brain network disruption that can cause cognitive impairment and interact with Alzheimer's pathology to produce mixed dementia.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper enumerates strokes and small vessel disease among common causes of dementia and mixed dementia (Alzheimer's + vascular) and highlights vascular contributions (cites vascular disorders in Table 1/2).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Narrative review / clinical guidance</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper does not quantify the relative contribution compared with pure Alzheimer's disease; emphasizes need to evaluate vascular comorbidity.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e6171.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Cardio-metabolic (Diabetes/Obesity)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cardiovascular and metabolic risk factors (diabetes, obesity, hypertension)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Metabolic and cardiovascular conditions such as diabetes and obesity are listed as contributors to dementia risk.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>cardiometabolic / lifestyle</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Metabolic imbalances (e.g., diabetes, dyslipidemia, hypertension, obesity) lead to vascular injury, inflammation, and metabolic stress on neurons, increasing dementia risk.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper lists diabetes, obesity and cardiovascular disease among common causes/risk factors and cites Lancet review on dementia prevention and care (Livingston et al.).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Narrative review citing epidemiologic literature</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper recommends managing comorbidities but does not provide effect sizes or interventional trial outcomes in this text.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e6171.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Lifestyle (Exercise/Diet/Smoking/Alcohol)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Lifestyle factors: physical inactivity, poor diet, smoking, heavy alcohol use</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Lifestyle behaviors including lack of exercise, poor diet, smoking and heavy alcohol use are listed as modifiable risk factors for dementia/Alzheimer's disease.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>lifestyle / environmental</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Sedentary behavior, unhealthy diet, smoking and excessive alcohol consumption contribute to cardiovascular and metabolic disease, oxidative stress and neuroinflammation, thereby increasing dementia risk.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper includes these factors in lists of risk contributors and cites broader dementia prevention literature (e.g., Livingston et al.) supporting lifestyle modification as prevention/mitigation.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Narrative review and clinical guidance</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper advocates lifestyle modification for prevention but does not provide specific quantified reductions in risk in this toolkit.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e6171.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Sleep deficits / Sleep apnea</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Sleep deficits and obstructive sleep apnea</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Chronic sleep deprivation and obstructive sleep apnea are described as contributors to cognitive decline.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>physiological / modifiable</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Chronic inadequate sleep and sleep-disordered breathing impair memory consolidation, promote cerebrovascular stress and may increase accumulation of pathological proteins, contributing to cognitive impairment.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper lists sleep apnea and sleep deficits among causes of cognitive impairment and reversible contributors to evaluate during workup.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Narrative review / clinical recommendations</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper notes sleep problems are a modifiable target but does not supply detailed trial evidence here.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e6171.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Infections / Delirium</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Acute infections and delirium (e.g., urinary tract infections, pneumonia)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Acute systemic infections are described as causes of delirium and transient cognitive worsening that can mimic or exacerbate dementia.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>infectious / reversible</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Systemic infections can provoke delirium and acute cognitive decline via inflammation, metabolic disturbance and reduced cerebral oxygenation; treating the infection can reverse cognitive symptoms.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper specifically lists UTIs and pneumonia as causes of delirium and cognitive worsening and emphasizes evaluating for these reversible causes in workup.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical guidance / narrative review</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper emphasizes differentiation between delirium (often reversible) and chronic neurodegenerative disease; does not provide incidence rates.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e6171.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Medications / Polypharmacy</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Medication side effects and polypharmacy</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Certain prescription and over-the-counter medications (e.g., some statins, chemotherapy drugs, pain meds, anxiolytics, sleeping pills) can cause cognitive impairment as side effects.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>iatrogenic / reversible</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Adverse drug effects and drug interactions can impair cognition via anticholinergic effects, sedation, metabolic disruption or other mechanisms; brown-bag medication review can identify reversible contributors.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper lists medication reactions and recommends medication review (brown bag) as part of evaluation to identify reversible causes; includes examples of medication classes.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical practice guidance</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper recommends medication reconciliation but does not quantify prevalence or strength of effect of specific drugs on cognitive trajectories.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e6171.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Vitamin B12 / Nutritional Deficiency</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Vitamin B12 deficiency and other nutritional deficiencies</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Nutritional deficiencies such as vitamin B12 deficiency are listed as treatable causes of cognitive impairment that can mimic dementia.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>nutritional / reversible</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Vitamin B12 deficiency impairs myelin synthesis and neuronal function and can cause memory loss and behavioral changes; identifying and correcting deficiency can improve cognition.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper lists B12 deficiency among common reversible causes in Table 3 and recommends laboratory testing during workup.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical guidance / narrative summary</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper notes treatable but also that delayed diagnosis may limit reversibility; no prevalence numbers provided.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e6171.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Toxins / Environmental</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Environmental toxins (pesticides, drinking-water contaminants, heavy metals, air pollutants)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Potential environmental exposures are discussed as ongoing research areas that may affect cognition and dementia risk.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>environmental / toxic</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Chronic exposure to certain toxins (e.g., pesticides, heavy metals, water contaminants, air pollution) may damage neurons, promote inflammation or impair vascular function, contributing to cognitive decline.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper mentions ongoing research about effects of toxins and lists them among possible causes to consider; frames this as an area of active study rather than established causal proof.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Narrative review; points to ongoing research</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper notes research is ongoing and does not present definitive evidence or metrics; treated as potential contributors requiring further study.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e6171.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Amyloid PET / CSF tau & amyloid</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Amyloid PET imaging and cerebrospinal fluid (CSF) amyloid/tau biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Imaging (amyloid PET) and CSF assays for amyloid-beta and tau are presented as modern diagnostic tools that correlate with Alzheimer's pathology and can diagnose early-stage disease prior to autopsy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>biomarker / detection_method</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Amyloid PET detects fibrillar amyloid-beta plaque deposition in vivo; CSF assays measure levels of amyloid-beta species and tau (total and phosphorylated) reflecting neuropathological processes of Alzheimer's disease.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper states these tests 'have been used in the clinical diagnosis' and 'some correlated well with pathological processes and can make accurate diagnosis of Alzheimer's disease prior to autopsy.'</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Amyloid PET imaging; CSF amyloid-beta and tau assays</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Amyloid PET uses radioligands to visualize amyloid plaque burden in the brain; CSF tests quantify amyloid-beta and tau proteins from lumbar puncture.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper reports these tests can 'accurately diagnose early-stage Alzheimer's' and 'correlate well with pathological processes' but provides no numerical sensitivity/specificity metrics within this article.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Preclinical and early-stage Alzheimers disease (can detect pathology prior to clinical dementia)</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical diagnostic studies referenced in narrative review</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper notes these tests exist but does not provide numeric performance; also emphasizes that no single diagnostic test is definitive and that full clinical evaluation is required. Practical limitations (cost, availability, invasiveness of LP, and PET access) are implied though not quantified.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.13">
                <h3 class="extraction-instance">Extracted Data Instance 13 (e6171.13)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Plasma / Blood biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Plasma and blood biomarker tests (amyloid/tau/plasma panels)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Blood/plasma biomarker tests for amyloid/tau are discussed as emerging tools but described as currently less predictive than CSF/PET in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>biomarker / detection_method</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Plasma biomarker assays measure amyloid-beta species, phosphorylated tau, or other proteins in blood that may reflect central nervous system Alzheimer's pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper mentions 'tau and plasma tests' and references research (e.g., Cullen et al. 2021) on plasma biomarker combinations for prognosis in MCI; indicates potential for early diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Paper explicitly states 'Blood biomarkers, however, are less predictive' compared to CSF/PET within the discussed literature.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Plasma/blood biomarker assays (amyloid, tau, combined panels)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Minimally invasive blood tests measuring Alzheimer's-related proteins or panels intended to predict pathology or prognosis.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper states blood biomarkers are 'less predictive' than CSF/PET and cites studies exploring plasma combinations for individualized prognosis, but provides no specific sensitivity/specificity numbers in this article.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Potentially preclinical and MCI (research stage for prognostic use)</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Emerging clinical research / referenced cohort biomarker studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper highlights lower predictive value currently and implies further validation is needed; no numeric performance data provided here.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.14">
                <h3 class="extraction-instance">Extracted Data Instance 14 (e6171.14)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Cognitive screening tests (general)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Brief cognitive screening tests (MMSE, MoCA, Mini-Cog, MIS, SLUMS, GPCOG, AD8, IQCODE, RUDAS, Clock Drawing)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A range of brief paper-pencil or informant cognitive screening instruments are described as practical first-step tools for detecting possible cognitive impairment in primary care.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>detection_method</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Brief cognitive tests assess domains such as memory, orientation, language, executive function and visuospatial skills to screen for objective cognitive change; informant questionnaires collect observed functional decline.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper lists many tools (MMSE, Mini-Cog, MIS, MoCA, SLUMS, GPCOG, AD8, Short IQCODE, RUDAS, Clock Drawing) and cites validation studies and reviews for several (e.g., MMSE widely used; Mini-Cog 35 min; MIS, MoCA validity references).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Brief cognitive screening instruments (MMSE, MoCA, Mini-Cog, MIS, GPCOG, AD8, Short IQCODE, RUDAS, Clock Drawing, SLUMS)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Short structured tests administered in primary care (typically <10 minutes) assessing cognitive domains; some combine patient tasks (recall, clock drawing) and informant reports (AD8, IQCODE).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper provides operational details (e.g., Mini-Cog 35 minutes; MMSE ~10 minutes) and notes that many tools are validated but does not report unified sensitivity/specificity numbers; it cautions that screening tests are not diagnostic and require full workup. It also notes that some tests need adjustment for age, education and race/ethnicity.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Mild cognitive impairment and dementia screening; can detect possible cognitive change in pre-dementia stages but are not diagnostic of AD pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical validation studies referenced; summary of guideline recommendations</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper stresses limitations: screening tests are not diagnostic, may be influenced by education, language, culture, hearing/vision, and literacy; some tools lack formal testing in primary care uptake. Medicare AWV requires cognitive assessment but evidence for routine annual screening is stated as 'insufficient'.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.15">
                <h3 class="extraction-instance">Extracted Data Instance 15 (e6171.15)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Informant-based tools (AD8 / IQCODE)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Informant questionnaires: AD8 and Short IQCODE</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Informant-report instruments (AD8, Short IQCODE) collect observations from family/friends and are recommended to complement patient screening.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>detection_method</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>These tools ask a knowledgeable informant about changes in the patient's cognition and function over time, improving detection when patients lack insight.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper recommends collecting symptoms via AD8 or Short IQCODE concurrently with patient testing, noting this provides additional insight and helps monitor response to interventions.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>AD8 informant interview; Short IQCODE questionnaire</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Structured informant questionnaires that score reported change in memory and function to flag possible cognitive impairment.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper asserts these tools are useful for gathering symptoms and monitoring change but does not provide numeric performance metrics in this article; references validate their utility in practice.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Useful across early subjective decline, MCI and dementia for detecting functional change</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Referenced validation studies / clinical tools</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Effectiveness depends on availability of a reliable informant and cultural/language appropriateness; paper recommends concurrent use with objective testing.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.16">
                <h3 class="extraction-instance">Extracted Data Instance 16 (e6171.16)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Digital cognitive assessments</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Digital cognitive assessment tools</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Digital or computerized cognitive assessments are discussed as potentially enhancing efficiency of evaluations in neurology and other clinics.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>detection_method (digital)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Computerized or tablet-based tests that administer cognitive tasks, record performance, and may offer rapid scoring and longitudinal tracking.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper cites Staffaroni et al. (2020) suggesting digital assessments may enhance efficiency of evaluations and clinics.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Digital cognitive assessments</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Automated computerized cognitive batteries administered in clinic or remotely to screen and track cognitive performance over time.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper suggests potential efficiency gains but does not provide numerical performance metrics; indicates digital tools may improve workflow.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Screening and monitoring across subjective decline, MCI and dementia (context-dependent)</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Referenced methodological/clinical practice literature</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Practical limitations include need for validation in diverse primary care settings, digital literacy, access disparities, and integration into EHR/workflow; paper emphasizes training and cultural considerations.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6171.17">
                <h3 class="extraction-instance">Extracted Data Instance 17 (e6171.17)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Diagnostic workup (clinical + imaging/labs)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Comprehensive clinical diagnostic evaluation (history, physical, labs, imaging, specialist input)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Paper emphasizes that no single test diagnoses Alzheimer's; a complete diagnostic evaluation includes clinical history, informant report, mood screening, medication review, lab tests for reversible causes and brain imaging.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>detection_method (clinical multimodal)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Integrative diagnostic approach combining cognitive testing, informant history, medical evaluation, laboratory testing for reversible causes (thyroid, B12, metabolic), medication review, and brain imaging to rule out other causes.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper states a diagnosis requires elimination of other causes and a multidisciplinary evaluation; this approach is standard clinical practice supported by guideline citations.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Multimodal clinical diagnostic workup (history, informant, lab tests, imaging, specialist assessment)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>A full 'workup' includes screening for mood, medications, laboratory tests for reversible causes, and brain imaging to support differential diagnosis and identify reversible contributors.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper emphasizes clinical judgment and combination testing produce reasonable diagnostic certainty but provides no single performance metric; states 'no single diagnostic test' exists.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>MCI through dementia; can help rule out reversible causes across stages</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical guideline / narrative review</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper highlights barriers to implementing comprehensive workups in primary care (time, training, cultural competence) and that many tools/tests may be inaccessible or underutilized.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Dementia prevention, intervention, and care <em>(Rating: 2)</em></li>
                <li>Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations <em>(Rating: 2)</em></li>
                <li>Diagnosis of early Alzheimer's disease: Clinical practice in 2021 <em>(Rating: 2)</em></li>
                <li>The characterization of subjective cognitive decline <em>(Rating: 1)</em></li>
                <li>Digital Cognitive Assessments for Dementia: Digital assessments may enhance the efficiency of evaluations in neurology and other clinics <em>(Rating: 1)</em></li>
                <li>Depression-an underrecognized target for prevention of dementia in Alzheimer's disease <em>(Rating: 1)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-6171",
    "paper_id": "paper-252611174",
    "extraction_schema_id": "extraction-schema-123",
    "extracted_data": [
        {
            "name_short": "Age",
            "name_full": "Advanced age",
            "brief_description": "Chronological aging identified in the paper as the leading risk factor for Alzheimer's disease; risk rises with increasing age.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "age",
            "cause_description": "Increasing chronological age is the primary risk factor for Alzheimer's disease; age-related biological changes increase vulnerability to neurodegenerative processes.",
            "evidence_for_cause": "Cited as 'age is the leading risk factor' referencing the National Institute on Aging and general epidemiologic consensus (paper cites NIA fact sheet and Alzheimer's Association summaries).",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Narrative review / guideline-style review",
            "study_population": null,
            "limitations_or_counterpoints": "Paper notes age is a non-modifiable risk factor; does not provide quantitative risk estimates or age cutoffs beyond referencing standard epidemiology.",
            "uuid": "e6171.0"
        },
        {
            "name_short": "Family history / Genetics",
            "name_full": "Family history and genetic predisposition",
            "brief_description": "Family history/genetic predisposition is listed among risk factors for dementia/Alzheimer's disease in the paper.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "genetic",
            "cause_description": "Heritable genetic factors and family history increase risk of Alzheimer's disease through inherited variants that affect amyloid, tau, or other pathways (paper lists family history as a risk factor but does not elaborate mechanisms).",
            "evidence_for_cause": "Listed among common risk factors; supported by cited background references (e.g., NIA and Alzheimer's Association materials referenced in paper).",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Narrative review / literature summary",
            "study_population": null,
            "limitations_or_counterpoints": "Paper does not detail which genes or quantify risk; genetic risk is presented qualitatively only.",
            "uuid": "e6171.1"
        },
        {
            "name_short": "Depression",
            "name_full": "Depression (affective disorder)",
            "brief_description": "Depression is listed both as a possible reversible contributor to cognitive impairment and as an underrecognized target for dementia prevention.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "psychiatric / modifiable risk",
            "cause_description": "Depressive symptoms and major depression in midlife or later life are associated with increased risk of cognitive decline and dementia; may act via behavioral, vascular, inflammatory, or neuroendocrine mechanisms (paper notes depression as both a reversible cause and preventive target).",
            "evidence_for_cause": "Paper cites literature noting depression as an underrecognized prevention target (references e.g., Dafsari & Jessen 2020) and lists depression among causes to assess and treat as part of reversible contributors.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Narrative review; cites relevant clinical reviews",
            "study_population": null,
            "limitations_or_counterpoints": "Paper does not provide causal proof or effect sizes; frames depression as potentially remediable contributor and target for prevention rather than proven causal pathology.",
            "uuid": "e6171.2"
        },
        {
            "name_short": "Traumatic Brain Injury",
            "name_full": "Traumatic brain injury (TBI) / head injury",
            "brief_description": "Head injuries are listed as associated with temporary or long-lasting cognitive impairment and as a risk factor for later dementia.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "environmental / injury",
            "cause_description": "TBI can damage brain tissue and initiate processes that cause cognitive decline; repeated or severe head trauma can lead to chronic neurodegeneration.",
            "evidence_for_cause": "Paper lists head injuries among causes of cognitive impairment and notes association with longer-lasting impairment; draws on general literature linking TBI with later cognitive problems.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Narrative review / summary of causes",
            "study_population": null,
            "limitations_or_counterpoints": "No quantitative risk estimates provided; paper treats TBI as one of several risk contributors without detailing dose-response or moderating factors.",
            "uuid": "e6171.3"
        },
        {
            "name_short": "Vascular / Stroke",
            "name_full": "Vascular disease and stroke (cerebral small vessel disease)",
            "brief_description": "Vascular injury, stroke and cerebral small vessel disease are listed as causes of cognitive impairment and contributors to mixed dementia.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "vascular",
            "cause_description": "Impaired blood flow, strokes, and small vessel disease produce neuronal injury and brain network disruption that can cause cognitive impairment and interact with Alzheimer's pathology to produce mixed dementia.",
            "evidence_for_cause": "Paper enumerates strokes and small vessel disease among common causes of dementia and mixed dementia (Alzheimer's + vascular) and highlights vascular contributions (cites vascular disorders in Table 1/2).",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Narrative review / clinical guidance",
            "study_population": null,
            "limitations_or_counterpoints": "Paper does not quantify the relative contribution compared with pure Alzheimer's disease; emphasizes need to evaluate vascular comorbidity.",
            "uuid": "e6171.4"
        },
        {
            "name_short": "Cardio-metabolic (Diabetes/Obesity)",
            "name_full": "Cardiovascular and metabolic risk factors (diabetes, obesity, hypertension)",
            "brief_description": "Metabolic and cardiovascular conditions such as diabetes and obesity are listed as contributors to dementia risk.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "cardiometabolic / lifestyle",
            "cause_description": "Metabolic imbalances (e.g., diabetes, dyslipidemia, hypertension, obesity) lead to vascular injury, inflammation, and metabolic stress on neurons, increasing dementia risk.",
            "evidence_for_cause": "Paper lists diabetes, obesity and cardiovascular disease among common causes/risk factors and cites Lancet review on dementia prevention and care (Livingston et al.).",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Narrative review citing epidemiologic literature",
            "study_population": null,
            "limitations_or_counterpoints": "Paper recommends managing comorbidities but does not provide effect sizes or interventional trial outcomes in this text.",
            "uuid": "e6171.5"
        },
        {
            "name_short": "Lifestyle (Exercise/Diet/Smoking/Alcohol)",
            "name_full": "Lifestyle factors: physical inactivity, poor diet, smoking, heavy alcohol use",
            "brief_description": "Lifestyle behaviors including lack of exercise, poor diet, smoking and heavy alcohol use are listed as modifiable risk factors for dementia/Alzheimer's disease.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "lifestyle / environmental",
            "cause_description": "Sedentary behavior, unhealthy diet, smoking and excessive alcohol consumption contribute to cardiovascular and metabolic disease, oxidative stress and neuroinflammation, thereby increasing dementia risk.",
            "evidence_for_cause": "Paper includes these factors in lists of risk contributors and cites broader dementia prevention literature (e.g., Livingston et al.) supporting lifestyle modification as prevention/mitigation.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Narrative review and clinical guidance",
            "study_population": null,
            "limitations_or_counterpoints": "Paper advocates lifestyle modification for prevention but does not provide specific quantified reductions in risk in this toolkit.",
            "uuid": "e6171.6"
        },
        {
            "name_short": "Sleep deficits / Sleep apnea",
            "name_full": "Sleep deficits and obstructive sleep apnea",
            "brief_description": "Chronic sleep deprivation and obstructive sleep apnea are described as contributors to cognitive decline.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "physiological / modifiable",
            "cause_description": "Chronic inadequate sleep and sleep-disordered breathing impair memory consolidation, promote cerebrovascular stress and may increase accumulation of pathological proteins, contributing to cognitive impairment.",
            "evidence_for_cause": "Paper lists sleep apnea and sleep deficits among causes of cognitive impairment and reversible contributors to evaluate during workup.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Narrative review / clinical recommendations",
            "study_population": null,
            "limitations_or_counterpoints": "Paper notes sleep problems are a modifiable target but does not supply detailed trial evidence here.",
            "uuid": "e6171.7"
        },
        {
            "name_short": "Infections / Delirium",
            "name_full": "Acute infections and delirium (e.g., urinary tract infections, pneumonia)",
            "brief_description": "Acute systemic infections are described as causes of delirium and transient cognitive worsening that can mimic or exacerbate dementia.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "infectious / reversible",
            "cause_description": "Systemic infections can provoke delirium and acute cognitive decline via inflammation, metabolic disturbance and reduced cerebral oxygenation; treating the infection can reverse cognitive symptoms.",
            "evidence_for_cause": "Paper specifically lists UTIs and pneumonia as causes of delirium and cognitive worsening and emphasizes evaluating for these reversible causes in workup.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Clinical guidance / narrative review",
            "study_population": null,
            "limitations_or_counterpoints": "Paper emphasizes differentiation between delirium (often reversible) and chronic neurodegenerative disease; does not provide incidence rates.",
            "uuid": "e6171.8"
        },
        {
            "name_short": "Medications / Polypharmacy",
            "name_full": "Medication side effects and polypharmacy",
            "brief_description": "Certain prescription and over-the-counter medications (e.g., some statins, chemotherapy drugs, pain meds, anxiolytics, sleeping pills) can cause cognitive impairment as side effects.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "iatrogenic / reversible",
            "cause_description": "Adverse drug effects and drug interactions can impair cognition via anticholinergic effects, sedation, metabolic disruption or other mechanisms; brown-bag medication review can identify reversible contributors.",
            "evidence_for_cause": "Paper lists medication reactions and recommends medication review (brown bag) as part of evaluation to identify reversible causes; includes examples of medication classes.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Clinical practice guidance",
            "study_population": null,
            "limitations_or_counterpoints": "Paper recommends medication reconciliation but does not quantify prevalence or strength of effect of specific drugs on cognitive trajectories.",
            "uuid": "e6171.9"
        },
        {
            "name_short": "Vitamin B12 / Nutritional Deficiency",
            "name_full": "Vitamin B12 deficiency and other nutritional deficiencies",
            "brief_description": "Nutritional deficiencies such as vitamin B12 deficiency are listed as treatable causes of cognitive impairment that can mimic dementia.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "nutritional / reversible",
            "cause_description": "Vitamin B12 deficiency impairs myelin synthesis and neuronal function and can cause memory loss and behavioral changes; identifying and correcting deficiency can improve cognition.",
            "evidence_for_cause": "Paper lists B12 deficiency among common reversible causes in Table 3 and recommends laboratory testing during workup.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Clinical guidance / narrative summary",
            "study_population": null,
            "limitations_or_counterpoints": "Paper notes treatable but also that delayed diagnosis may limit reversibility; no prevalence numbers provided.",
            "uuid": "e6171.10"
        },
        {
            "name_short": "Toxins / Environmental",
            "name_full": "Environmental toxins (pesticides, drinking-water contaminants, heavy metals, air pollutants)",
            "brief_description": "Potential environmental exposures are discussed as ongoing research areas that may affect cognition and dementia risk.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "environmental / toxic",
            "cause_description": "Chronic exposure to certain toxins (e.g., pesticides, heavy metals, water contaminants, air pollution) may damage neurons, promote inflammation or impair vascular function, contributing to cognitive decline.",
            "evidence_for_cause": "Paper mentions ongoing research about effects of toxins and lists them among possible causes to consider; frames this as an area of active study rather than established causal proof.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": null,
            "study_type": "Narrative review; points to ongoing research",
            "study_population": null,
            "limitations_or_counterpoints": "Paper notes research is ongoing and does not present definitive evidence or metrics; treated as potential contributors requiring further study.",
            "uuid": "e6171.11"
        },
        {
            "name_short": "Amyloid PET / CSF tau & amyloid",
            "name_full": "Amyloid PET imaging and cerebrospinal fluid (CSF) amyloid/tau biomarkers",
            "brief_description": "Imaging (amyloid PET) and CSF assays for amyloid-beta and tau are presented as modern diagnostic tools that correlate with Alzheimer's pathology and can diagnose early-stage disease prior to autopsy.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "biomarker / detection_method",
            "cause_description": "Amyloid PET detects fibrillar amyloid-beta plaque deposition in vivo; CSF assays measure levels of amyloid-beta species and tau (total and phosphorylated) reflecting neuropathological processes of Alzheimer's disease.",
            "evidence_for_cause": "Paper states these tests 'have been used in the clinical diagnosis' and 'some correlated well with pathological processes and can make accurate diagnosis of Alzheimer's disease prior to autopsy.'",
            "evidence_against_cause": null,
            "detection_method": "Amyloid PET imaging; CSF amyloid-beta and tau assays",
            "detection_method_description": "Amyloid PET uses radioligands to visualize amyloid plaque burden in the brain; CSF tests quantify amyloid-beta and tau proteins from lumbar puncture.",
            "detection_performance": "Paper reports these tests can 'accurately diagnose early-stage Alzheimer's' and 'correlate well with pathological processes' but provides no numerical sensitivity/specificity metrics within this article.",
            "disease_stage_detected": "Preclinical and early-stage Alzheimers disease (can detect pathology prior to clinical dementia)",
            "study_type": "Clinical diagnostic studies referenced in narrative review",
            "study_population": null,
            "limitations_or_counterpoints": "Paper notes these tests exist but does not provide numeric performance; also emphasizes that no single diagnostic test is definitive and that full clinical evaluation is required. Practical limitations (cost, availability, invasiveness of LP, and PET access) are implied though not quantified.",
            "uuid": "e6171.12"
        },
        {
            "name_short": "Plasma / Blood biomarkers",
            "name_full": "Plasma and blood biomarker tests (amyloid/tau/plasma panels)",
            "brief_description": "Blood/plasma biomarker tests for amyloid/tau are discussed as emerging tools but described as currently less predictive than CSF/PET in this paper.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "biomarker / detection_method",
            "cause_description": "Plasma biomarker assays measure amyloid-beta species, phosphorylated tau, or other proteins in blood that may reflect central nervous system Alzheimer's pathology.",
            "evidence_for_cause": "Paper mentions 'tau and plasma tests' and references research (e.g., Cullen et al. 2021) on plasma biomarker combinations for prognosis in MCI; indicates potential for early diagnosis.",
            "evidence_against_cause": "Paper explicitly states 'Blood biomarkers, however, are less predictive' compared to CSF/PET within the discussed literature.",
            "detection_method": "Plasma/blood biomarker assays (amyloid, tau, combined panels)",
            "detection_method_description": "Minimally invasive blood tests measuring Alzheimer's-related proteins or panels intended to predict pathology or prognosis.",
            "detection_performance": "Paper states blood biomarkers are 'less predictive' than CSF/PET and cites studies exploring plasma combinations for individualized prognosis, but provides no specific sensitivity/specificity numbers in this article.",
            "disease_stage_detected": "Potentially preclinical and MCI (research stage for prognostic use)",
            "study_type": "Emerging clinical research / referenced cohort biomarker studies",
            "study_population": null,
            "limitations_or_counterpoints": "Paper highlights lower predictive value currently and implies further validation is needed; no numeric performance data provided here.",
            "uuid": "e6171.13"
        },
        {
            "name_short": "Cognitive screening tests (general)",
            "name_full": "Brief cognitive screening tests (MMSE, MoCA, Mini-Cog, MIS, SLUMS, GPCOG, AD8, IQCODE, RUDAS, Clock Drawing)",
            "brief_description": "A range of brief paper-pencil or informant cognitive screening instruments are described as practical first-step tools for detecting possible cognitive impairment in primary care.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "use",
            "cause_type": "detection_method",
            "cause_description": "Brief cognitive tests assess domains such as memory, orientation, language, executive function and visuospatial skills to screen for objective cognitive change; informant questionnaires collect observed functional decline.",
            "evidence_for_cause": "Paper lists many tools (MMSE, Mini-Cog, MIS, MoCA, SLUMS, GPCOG, AD8, Short IQCODE, RUDAS, Clock Drawing) and cites validation studies and reviews for several (e.g., MMSE widely used; Mini-Cog 35 min; MIS, MoCA validity references).",
            "evidence_against_cause": null,
            "detection_method": "Brief cognitive screening instruments (MMSE, MoCA, Mini-Cog, MIS, GPCOG, AD8, Short IQCODE, RUDAS, Clock Drawing, SLUMS)",
            "detection_method_description": "Short structured tests administered in primary care (typically &lt;10 minutes) assessing cognitive domains; some combine patient tasks (recall, clock drawing) and informant reports (AD8, IQCODE).",
            "detection_performance": "Paper provides operational details (e.g., Mini-Cog 35 minutes; MMSE ~10 minutes) and notes that many tools are validated but does not report unified sensitivity/specificity numbers; it cautions that screening tests are not diagnostic and require full workup. It also notes that some tests need adjustment for age, education and race/ethnicity.",
            "disease_stage_detected": "Mild cognitive impairment and dementia screening; can detect possible cognitive change in pre-dementia stages but are not diagnostic of AD pathology.",
            "study_type": "Clinical validation studies referenced; summary of guideline recommendations",
            "study_population": null,
            "limitations_or_counterpoints": "Paper stresses limitations: screening tests are not diagnostic, may be influenced by education, language, culture, hearing/vision, and literacy; some tools lack formal testing in primary care uptake. Medicare AWV requires cognitive assessment but evidence for routine annual screening is stated as 'insufficient'.",
            "uuid": "e6171.14"
        },
        {
            "name_short": "Informant-based tools (AD8 / IQCODE)",
            "name_full": "Informant questionnaires: AD8 and Short IQCODE",
            "brief_description": "Informant-report instruments (AD8, Short IQCODE) collect observations from family/friends and are recommended to complement patient screening.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "use",
            "cause_type": "detection_method",
            "cause_description": "These tools ask a knowledgeable informant about changes in the patient's cognition and function over time, improving detection when patients lack insight.",
            "evidence_for_cause": "Paper recommends collecting symptoms via AD8 or Short IQCODE concurrently with patient testing, noting this provides additional insight and helps monitor response to interventions.",
            "evidence_against_cause": null,
            "detection_method": "AD8 informant interview; Short IQCODE questionnaire",
            "detection_method_description": "Structured informant questionnaires that score reported change in memory and function to flag possible cognitive impairment.",
            "detection_performance": "Paper asserts these tools are useful for gathering symptoms and monitoring change but does not provide numeric performance metrics in this article; references validate their utility in practice.",
            "disease_stage_detected": "Useful across early subjective decline, MCI and dementia for detecting functional change",
            "study_type": "Referenced validation studies / clinical tools",
            "study_population": null,
            "limitations_or_counterpoints": "Effectiveness depends on availability of a reliable informant and cultural/language appropriateness; paper recommends concurrent use with objective testing.",
            "uuid": "e6171.15"
        },
        {
            "name_short": "Digital cognitive assessments",
            "name_full": "Digital cognitive assessment tools",
            "brief_description": "Digital or computerized cognitive assessments are discussed as potentially enhancing efficiency of evaluations in neurology and other clinics.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "mention",
            "cause_type": "detection_method (digital)",
            "cause_description": "Computerized or tablet-based tests that administer cognitive tasks, record performance, and may offer rapid scoring and longitudinal tracking.",
            "evidence_for_cause": "Paper cites Staffaroni et al. (2020) suggesting digital assessments may enhance efficiency of evaluations and clinics.",
            "evidence_against_cause": null,
            "detection_method": "Digital cognitive assessments",
            "detection_method_description": "Automated computerized cognitive batteries administered in clinic or remotely to screen and track cognitive performance over time.",
            "detection_performance": "Paper suggests potential efficiency gains but does not provide numerical performance metrics; indicates digital tools may improve workflow.",
            "disease_stage_detected": "Screening and monitoring across subjective decline, MCI and dementia (context-dependent)",
            "study_type": "Referenced methodological/clinical practice literature",
            "study_population": null,
            "limitations_or_counterpoints": "Practical limitations include need for validation in diverse primary care settings, digital literacy, access disparities, and integration into EHR/workflow; paper emphasizes training and cultural considerations.",
            "uuid": "e6171.16"
        },
        {
            "name_short": "Diagnostic workup (clinical + imaging/labs)",
            "name_full": "Comprehensive clinical diagnostic evaluation (history, physical, labs, imaging, specialist input)",
            "brief_description": "Paper emphasizes that no single test diagnoses Alzheimer's; a complete diagnostic evaluation includes clinical history, informant report, mood screening, medication review, lab tests for reversible causes and brain imaging.",
            "citation_title": "The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia",
            "mention_or_use": "use",
            "cause_type": "detection_method (clinical multimodal)",
            "cause_description": "Integrative diagnostic approach combining cognitive testing, informant history, medical evaluation, laboratory testing for reversible causes (thyroid, B12, metabolic), medication review, and brain imaging to rule out other causes.",
            "evidence_for_cause": "Paper states a diagnosis requires elimination of other causes and a multidisciplinary evaluation; this approach is standard clinical practice supported by guideline citations.",
            "evidence_against_cause": null,
            "detection_method": "Multimodal clinical diagnostic workup (history, informant, lab tests, imaging, specialist assessment)",
            "detection_method_description": "A full 'workup' includes screening for mood, medications, laboratory tests for reversible causes, and brain imaging to support differential diagnosis and identify reversible contributors.",
            "detection_performance": "Paper emphasizes clinical judgment and combination testing produce reasonable diagnostic certainty but provides no single performance metric; states 'no single diagnostic test' exists.",
            "disease_stage_detected": "MCI through dementia; can help rule out reversible causes across stages",
            "study_type": "Clinical guideline / narrative review",
            "study_population": null,
            "limitations_or_counterpoints": "Paper highlights barriers to implementing comprehensive workups in primary care (time, training, cultural competence) and that many tools/tests may be inaccessible or underutilized.",
            "uuid": "e6171.17"
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "Dementia prevention, intervention, and care",
            "rating": 2,
            "sanitized_title": "dementia_prevention_intervention_and_care"
        },
        {
            "paper_title": "Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations",
            "rating": 2,
            "sanitized_title": "individualized_prognosis_of_cognitive_decline_and_dementia_in_mild_cognitive_impairment_based_on_plasma_biomarker_combinations"
        },
        {
            "paper_title": "Diagnosis of early Alzheimer's disease: Clinical practice in 2021",
            "rating": 2,
            "sanitized_title": "diagnosis_of_early_alzheimers_disease_clinical_practice_in_2021"
        },
        {
            "paper_title": "The characterization of subjective cognitive decline",
            "rating": 1,
            "sanitized_title": "the_characterization_of_subjective_cognitive_decline"
        },
        {
            "paper_title": "Digital Cognitive Assessments for Dementia: Digital assessments may enhance the efficiency of evaluations in neurology and other clinics",
            "rating": 1,
            "sanitized_title": "digital_cognitive_assessments_for_dementia_digital_assessments_may_enhance_the_efficiency_of_evaluations_in_neurology_and_other_clinics"
        },
        {
            "paper_title": "Depression-an underrecognized target for prevention of dementia in Alzheimer's disease",
            "rating": 1,
            "sanitized_title": "depressionan_underrecognized_target_for_prevention_of_dementia_in_alzheimers_disease"
        }
    ],
    "cost": 0.0201635,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia
Published: 27 September 2022</p>
<p>Allison B Reiss 
NYU Long Island School of Medicine
11501MineolaNYUSA</p>
<p>Donna De Levante Raphael 
National Memory Screening Program
Alzheimer's Foundation of America
322 Eighth Avenue10001New YorkNYUSA</p>
<p>Nathaniel A Chin 
Wisconsin Alzheimer's Disease Research Center (ADRC)
53726MadisonWI</p>
<p>Vivek Sinha 
Belleview Medical Partners
22314AlexandriaVAUSA</p>
<p>The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia</p>
<p>AIMS Public Health
94Published: 27 September 202210.3934/publichealth.2022047Received: 19 July 2022 Revised: 07 September 2022 Accepted: 13 September 2022Research article * Correspondence:Mild Cognitive ImpairmentAlzheimer's diseasedementiabrain healthprimary care physicianshealth care cliniciansAlzheimer's knowledgeearly detectiondiagnosis and managementcultural competencybarriers to diagnosisreversible dementiairreversible dementias
Primary care professionals play a critical role in the care of their patients. In clinical practice, early detection and diagnosis of Mild Cognitive Impairment, Alzheimer's disease and related dementia are often missed or delayed. Disclosure of diagnosis is not timely or not revealed. Though the methods that could improve early detection and diagnosis have remained the same over the decades with little change, they provide opportunities for early intervention, treatment and improvement in patient care. Emerging research suggests that though the disease process begins years prior to the clinical diagnosis, the healthcare system and health care professionals remain distant and reluctant to provide the service of annual cognitive assessment, which has been recommended by the Medicare program for older adults aged 65 years and older. Findings support that Alzheimer's disease and related cognitive impairments have gone under detected, underdiagnosed and undertreated. This article seeks to provide valuable and equitable information in the form of a clinician's guide for removing the barriers to early detection and diagnosis of cognitive impairments and offers an unprecedented opportunity to improve the clinical outcomes and care of older adults with various levels of cognitive decline, including mild cognitive impairment, Alzheimer's disease, and related dementias. This article provides information on understanding and addressing the challenges faced by health care professionals, including primary care clinicians; removing the barriers to cognitive assessments; educating this professional group on the importance of brain health, early detection, and diagnosis for their older adult patients; and 662AIMS Public HealthVolume 9, Issue 4, 661-689.providing these professionals with the ability to transfer their knowledge into more defined care planning. Until cognitive screening has been fully accepted and implemented for the optimal the care of older adults, health-related efforts should include the promotion and education of brain health, early detection, and diagnosis in the education of health care providers.AIMS Public HealthVolume 9, Issue 4, 661-689.PsycARTICLES, MedLINE and the National Institute on Aging. To remain relevant, we sought articles published over the past 5 years with minimal papers prior to the 5 years. The search strategy applied incorporated 40 selected articles using the Boolean method. This method allowed the use of a combination of modifiers with keywords such as MCI, Alzheimer's disease, dementia, brain health, assessments, primary care physicians. We extracted relevant literature for this research article that resulted in the following keywords: Mild Cognitive Impairment, Alzheimer's disease, dementia, brain health, primary care physicians, health care clinicians, Alzheimer's knowledge, early detection, diagnosis and management, cultural competency, barriers to diagnosis, reversible dementia, and irreversible dementias. The Patient/Population, Intervention, Comparison and Outcomes (PICO) question and framework were useful in guiding the search and locating relevant keywords for the article.ResultsResults revealed that there were extensive papers on best practices for clinicians, practice guidelines for early detection and the importance of early diagnosis and caring for one's patient with cognitive decline.Figure 1(Main Challenges Encountered in Clinical Practices That Overlap) shows the main overarching issues within the medical field. Context, evidence, and recommendations listed in the table below affect the early detection and diagnosis and care management of the patients. Through interpretation, it was agreed that, for optimal outcomes for the patient and their family caregivers, the clinician required the knowledge and understanding of the disease and what care management and support should look like for their patient with dementia. The steps to follow would be to initiate a conversation with patients, early detection, and diagnosis, followed by a multidisciplinary evaluation to rule out dementia. If the result is dementia, then that would be followed by providing a collaborative care plan with recommendations from other support teams followed by monitoring and disease management. Volume 9, Issue 4, 661-689.</p>
<p>Introduction</p>
<p>Primary care providers (PCPs), healthcare systems and practices vary regarding their practices' relevant information. This toolkit aims to provide options to PCPs with approaches and tools they can select to remove the barriers to conducting cognitive assessments for their patients. This toolkit will have a section for each step necessary to initiate and increase cognitive awareness, detection and diagnosis of cognitive impairment and medical care.</p>
<p>It is recommended by the Centers for Medicare &amp; Medicaid Services that each individual 65 years and over receive an annual evaluation of one's cognitive health status. Medicare's Annual Wellness Visit (AWV) for those aged 65 years and older requires direct cognitive assessments as one of the several components for preventative care [1]. This quality metric is vital because it can improve the health outcomes of individuals and their families. If the identification of cognitive problems can be diagnosed earlier, a thorough investigation into reversible causes can begin. Additionally, patients can be educated on lifestyle behaviors that may help improve or maintain cognitive function. Additionally, we can gain valuable insight into cognitive and behavioral issues as the individual experiences them within their healthcare system. Cognitive screenings will allow physicians and other clinicians to work with patients and families to proactively develop care plans and improve the quality of life for all. Cognitive assessments should be part of every senior's annual wellness visit.</p>
<p>Initial cognitive screenings typically take a few minutes and may include questioning the patient and the patient's family, observing the patient's interactions or using short verbal or written tests [2]. These initial memory screenings do not give a diagnosis. A diagnosis requires a full cognitive assessment. Due to various challenges and barriers in screenings, physicians may often skip this evaluation. Therefore, many older adults are usually diagnosed only when severely impaired (i.e., with a dramatic change in daily activity). Due to this delay, it is often too late for the individual to plan for their future, seek effective treatments that are only effective in the early stages of the disease or enter a clinical trial. Individuals have the right to understand what is happening to them and make informed decisions based on their current situation. Having a diagnosis and knowing of a disease affecting one's memory can help the individual and their family effectively engage with their health care team and their familiar environment.</p>
<p>Materials and methods</p>
<p>We systematically searched eight databases to secure relevant information pertaining to topics related to aging, gerontology, and geriatrics: ProQuest, Google scholar, PubMed, CINAHL, PsycINFO, </p>
<p>Cognitive impairment</p>
<p>Dementia</p>
<p>Dementia is the loss of cognitive functioning. Dementia is not a disease but a group of symptoms caused by other conditions [3]. Dementia is the most prevalent of brain disorders in older adults [3]. Globally, dementia is one of the leading causes of disabilities in older adults [3]. Dementia is the umbrella term used to describe the group of symptoms causing memory loss, language loss, reduced judgment, reduced problem-solving skills and other thinking skills severe enough to interfere with activities of daily living and social and occupational functioning.</p>
<p>3.1.2. Subjective cognitive decline (SCD) SCD is referred to as self-reported information of increased changes in cognition such as memory loss and confusion. SCD is a type of cognitive impairment. SCD is one of the earliest recognitions of developing symptoms of cognitive decline, Alzheimer's disease and related dementia [4].</p>
<p>Mild cognitive impairment (MCI) vs. Dementia</p>
<p>MCI can develop for multiple reasons. MCI is not considered dementia [5]. However, people with MCI may develop dementia. Mild Cognitive Impairment can be an early sign of Alzheimer's. Not everyone with MCI will develop the disease. A person with dementia can experience more critical cognitive challenges than a person with MCI. The differences between MCI and dementia are related to the severity of the individual's symptoms.</p>
<p>Subjective cognitive decline (SCD) vs. Mild cognitive impairment (MCI)</p>
<p>Subjective cognitive decline (SCD) is self-perceived by a person who is cognitively normal in the absence of objectively measured cognitive deficits [6]. Mild cognitive impairment (MCI) is viewed as a transitional stage that rests between the cognitive decline in normal aging and dementia [7].</p>
<p>Alzheimer's disease (AD)</p>
<p>Alzheimer's disease is the most common form of dementia. According to the National Institute of Aging (NIA), Alzheimer's is currently the seventh-leading cause of death in the United States [6]. It is a progressive brain disorder that slowly destroys memory, thinking skills and eventually the ability to carry out the simplest tasks, such as one's activities of daily living (ADLs). Age is the leading risk factor for Alzheimer's disease [8].</p>
<p>3.1.6. Dementia vs. Alzheimer's disease Dementia is the general term applied to the group of symptoms negatively impacting memory [8]. Dementia is not restricted only to memory and encompasses a decline in cognitive function as well as alterations in mood, behavior and personality [9]. At the same time, Alzheimer's disease is a specific and progressive disease causing slow but permanent memory loss while affecting cognitive function.  Decreased ability to perform complex tasks (e.g., planning dinner) or handle personal finances (e.g., paying bills)</p>
<p> Delusions -such as thinking they need to go to work, even though they no longer have a job  Lack of concern for hygiene and appearance  Requirements of assistance in choosing proper clothing to wear for day, season or occasion
3.2.3. Late (Severe)
In this stage, there is almost total memory loss.</p>
<p> The individual may recognize faces but forget names.</p>
<p> The individual may mistake a person for someone else.</p>
<p> There is a strong need for holding something close for tactile stimulation, nurturing, companionship and comfort.</p>
<p> Basic abilities such as eating, walking and sitting up fade during this period; the individual may no longer recognize when they are thirsty or hungry and will need help with all basic activities of daily living.</p>
<p>Risk factors of dementia</p>
<p>A person's physical and lifestyle behaviors often factor in raising their chances for dementia, including: 
 Age  Dementia</p>
<p>Cognitive screening and diagnosis</p>
<p>In the past, a definitive Alzheimer's disease diagnosis could not be made until after death if a brain autopsy is completed. However, in the past decade, there have been new diagnostic approaches such as the amyloid PET, CSF (cerebrospinal fluid) biomarkers and tau and plasma tests, which have been used in the clinical diagnosis of Alzheimer's disease. These tests can be used to accurately diagnose early-stage Alzheimer's disease. Some of these tests correlated well with pathological processes and can make accurate diagnosis of Alzheimer's disease prior to autopsy. Blood biomarkers, however, are less predictive [9,10]. Today, physicians can also diagnose Alzheimer's with reasonable certainty by conducting tests that can eliminate other causes of memory loss and confusion and by reviewing how the patient's symptoms align with the disease [9,10]. A cognitive screening requires several reliable tests to screen for Alzheimer's or related dementia. A screening test should not be used as a substitute for a complete diagnostic evaluation [9,10]. There is no single diagnostic test than can determine an Alzheimer's diagnosis [9,10]. A complete clinical diagnostic evaluation often includes the screening of other physicians who use various approaches and tools to help give an accurate diagnosis, such as:</p>
<p> It is the collection of symptoms from both the person and the informant. The collection of symptoms includes cognitive signs and functional symptoms, with screening for objective cognitive change through a brief test to determine if there is a potential presence of impairment [11,12]. This will also include a "full workup"/complete medical examination to include mood screening, more focused cognitive history, medication review, laboratory test (looking for reversible causes) and brain imaging [11][12][13]. Some of this is likely done by a specialist.</p>
<p>Challenges and barriers to cognitive screening</p>
<p>Though there are structured processes for other health conditions, there is none for cognitive diseases. There are no specific standardized tests or guidelines established for cognitive assessments [14,15]. The cognitive assessment and diagnosis approach has been reactive when patients raise issues or self-report their cognitive experiences or challenges [14,15]. This approach can make cognitive screenings challenging in a clinical setting. Some of these challenges may include the following:</p>
<p> The clinician does not have special training for cognitive screenings  Screenings cause a delay in the clinic's workflow  Time limitations, fear of giving a diagnosis  Lack of cultural competency in their patient's understanding of the cognitive changes  Not knowing how to start the conversation  Alzheimer's disease stigma  Fear of harm to the older patient by conducting a cognitive assessment that may lead to depression or anxiety  Discrimination With these challenges and barriers, many health care providers remain hesitant to initiate the concerns of cognitive testing with their older patients. Providers instead are waiting for the older adult or family member to initiate the conversation about their problems. Physicians are in an ideal position to observe potential signs of cognitive decline and ask pertinent questions. As the provider to the individual, you may have a long-established relationship with the individual and their family [16,17]. When the patient is concerned about any changes in their memory functioning, they would most likely take the concern to their providers [16,17]. However, older adults will rarely initiate the conversation about their cognitive challenges for various reasons [16,17]. Some reasons may include:</p>
<p> Fear  Cultural perceptions of the disease  Stigma  Historical experiences</p>
<p> Not believing there is a benefit to knowing about the disease  "Why bother? Dementia is incurable."</p>
<p>How to start the conversation</p>
<p>It is essential not to ignore the changes in an older adult's memory, mood, behavior or personality. It is critical to take the concerns seriously and assess the patient as early as possible. You are more likely to be able to determine the potential cause for the consideration of brain functioning changes. When memory problems are reported by the patient or observed by a family member or yourself, these changes should be documented in the patient's chart, followed by a screening and assessment [18,19].</p>
<p>For the best care outcome, it is essential to know and explain to the patient and their caregiver that not all cognitive changes or problems result from Alzheimer's disease and that various other possible causes affect the brain's optimal functioning [18,19]. Some of these causes may be side effects from medications or a combination of drugs, thyroid conditions, untreated depression or anxiety, metabolic and endocrine changes, obstructive sleep apnea, strokes, traumatic brain injuries, infections like urinary tract infections (UTIs), pneumonia, vitamin deficiencies, delirium caused by other illnesses, stress or, finally, a brain-specific disease like Alzheimer's disease. Many of these conditions that cause memory impairment are treatable or reversible. Other causes of cognitive impairment cannot be reversed; however, the symptoms may be treated, and quality of life can still be optimized.</p>
<p>Alzheimer's disease specifically and dementia in general have become terms that terrify many patients, hampering their willingness to disclose information about their symptoms to their physicians. That makes even more important how physicians approach a cognitive screening test conversation. Physicians must approach the topic of cognitive screening by maintaining the focus on the importance of getting a baseline test, looking for reversible causes and recommending lifestyle changes that can lead to improved overall function and wellbeing. Treat cognitive screenings as a necessary test like you would for blood work or cancer screening. This approach provides the patient with the understanding that a baseline test should be updated at least yearly. Evidence for routine annual cognitive screenings has been insufficient [18,19]. The initiation of a cognitive assessment relies mainly on self-reported symptoms, so physicians must engage patients and their families in healthy, proactive conversations about cognition as a normalized topic during their annual wellness visits.</p>
<p>Importance of cognitive assessments of older adults</p>
<p>Americans aged 65 and older are expected to double from 52 million in 2018 to 95 million by 2060. This older adult population has become more racially and ethnically diverse [19,20]. It is essential to know that the population has changed, with more older Americans than before. Because Alzheimer's disease is an age-related disease, many people develop Alzheimer's or already have it. The issues with cognitive impairment in older adults can result from various possible causes, as seen in the table below.  State of worse than normal mental function. Common in hospitalized older adults due to infection and other health problems.</p>
<p>Infections</p>
<p>Not as common in older adults as the other causes, but certain chronic or acute infections can affect brain cells directly.</p>
<p>If the infection is outside of the brain (pneumonia or UTI), it is considered delirium). Vascular injury "Vascular" damage to neurons means damage caused by problems with the blood vessels.</p>
<p>Such as strokes or some form of cerebral small vessel disease.</p>
<p>Traumatic injury</p>
<p>Head injuries are also associated with temporary or longer-lasting cognitive impairment. Neurodegenerative condition Neurodegenerative conditions tend to damage and kill neurons slowly.</p>
<p>This can cause mild cognitive impairment and then eventually dementia. The more common neurodegenerative disorders include Alzheimer's disease, Lewy-Body disease, Parkinson's disease and frontotemporal degeneration. Though not a neurodegenerative condition, patients with small vessel disease may experience MCI then a dementia status. Substance abuse Both acute intoxication and chronic overuse of certain substances can impair brain function.</p>
<p>Such as alcohol, illicit drugs or even prescription drugs.</p>
<p>Psychiatric illness Most psychiatric conditions can cause problems with memory, thinking and concentration.</p>
<p>Paranoia, depression, anxiety, mental illness, bipolar disorder, schizophrenia. Metabolic imbalances Abnormalities in one's blood chemistry leading to diabetes, heart disease, stroke, high blood pressure or dementia.</p>
<p>Abnormal levels of blood sodium, calcium or glucose; kidney or liver dysfunction.</p>
<p>Toxins</p>
<p>Toxins are another potential cause of cognitive impairment.</p>
<p>Research is ongoing about the effects of toxins people may be exposed to, such as pesticides, contaminants in drinking water, air pollutants, heavy metals and others. Confusion, difficulty concentrating, slowed thinking, a decline in the ability to analyze a situation and reduced ability to organize thoughts or actions. Creutzfeldt-Jakob disease Personal changes, memory loss, blurred vision or blindness, insomnia, difficulty speaking and swallowing.</p>
<p>Mixed dementia</p>
<p>Slowness of thought, difficulty planning, difficulty understanding and concentrating, changes in mood and behavior, memory and language loss.</p>
<p>It is essential to understand that there are reversible and non-reversible conditions and to first rule out the curable/treatable conditions before diagnosing Alzheimer's disease or related dementia. As shown in Table 1, there are many causes of cognitive impairment. Some of these cognitive impairment conditions, such as medication side effects and depression, can be reversed or improved with treatment options. Table 2 defines Neurodegenerative Conditions, also known as progressive dementias. Such conditions as Alzheimer's disease cannot be reversed. Symptoms, however, can be treated over a period of time, usually in the early stages of the disease. It is essential to acknowledge that cognitive assessments can offer the individual and their family opportunities to prepare for future predictable changes and address safety concerns that come along with the progression of the disease [20].</p>
<p>Many individuals with memory loss or behavioral changes choose to get a diagnosis to understand the challenges they are experiencing and what to expect in the progression of the disease. In contrast, at times, others and their families are very reluctant to reveal their concerns because of the fear of the diagnosis of Alzheimer's disease, the challenges of stigma upon diagnosis and the future it foreshadows [21]. This reluctance often occurs with individuals from different socio-cultural backgrounds, and the physician or other clinician needs to understand their beliefs and traditions to treat them further [21]. By engaging these individuals and their families and asking why or why not, you can then understand their position on the disease and their reluctance to undergo diagnosis and treatment and eventually move closer to the diagnosis. However, it is important to have a conversation to engage the patient and understand the differences. In this conversation, the physician or provider can explain the benefits of getting the assessment to discover what may be causing the individual's health concerns.</p>
<p>Pharmacological treatment options for memory loss related to Alzheimer's disease and other cognitive symptoms only help to control the symptoms, and these treatments are limited. None of these treatments can reverse, slow or cure the course of the disease. The pharmacological management approaches listed here are those currently FDA (Food and Drug Administration) approved for cognitive and functional deficits, including behavioral symptoms. The most common treatments for dementia are cholinesterase inhibitors: Donepezil (Aricept), Rivastigmine (Exelon) and Galantamine (Razadyne) can help with symptoms, particularly in the earlier stages, and can lead to delayed institutionalization and reduced caregiver burden [22]. Medications for moderate and severe Alzheimer's disease are Glutamate regulators such as Memantine (Namenda) and Cholinesterase inhibitor + glutamate (Namzaric), which can help with symptoms, particularly in the more severe stages [22]. A study from a Harvard memory clinic showed that patients showed a slower downward decline in cognitive symptoms and functional changes after three years based on questionnaires [22,23]. This example suggests that while these medications don't treat underlying disease pathology, they can have a meaningful subjective impact on people as they are changing.</p>
<p>The newest pharmacological approach that was recently approved in 2021 was Aducanumab. This amyloid beta-directed antibody mediation is also known as Aduhelm. This medication was designed to decrease the amount of beta-amyloid and remove specific forms of beta-amyloid that accumulated into plaques in the brain. Aduhelm was designed to be administered to patients intravenously (IV) with infusions every four weeks. Aduhelm had several adverse effects on patients, such as bleeding in and on the brain's surface, various allergic reactions, and temporary swelling of the brain, including symptoms of nausea, confusion, dizziness, vision changes and headaches. This drug came with a lot of controversy. The main points of controversy were that there was insufficient evidence of efficacy, that the medication created false hope and that the high price would negatively impact the patients financially.</p>
<p>Another option for providing care is the use of non-drug approaches. Some individuals and their families are adamant about not resorting to pharmacological treatments. This decision must be respected. There are many options for non-drug approaches that can manage behavioral symptoms. It is highly recommended to promote the use of non-drug approaches to your client first before issuing a prescribed medication.</p>
<p>Reversible dementias</p>
<p>Reversible dementias are conditions associated with cognitive or behavioral symptoms that can be resolved with treatment once the primary cause is treated. As seen below in Table 3 (Reversible dementias), dementia-like symptoms can be reversed with treatment. Many potential causes of reversible dementias have been identified, resulting in reversible neurocognitive function impairment in older adults. There are, however, treatable dementias that may not be curable due to the delay in diagnosis. </p>
<p>Common causes of reversible dementia</p>
<p>Why early detection matters</p>
<p>Over the years, research has been gradually revealing that early detection of cognitive change can help to extend the longevity of the patient and enhance the quality of life for those who are eventually diagnosed with a cognitive disease and their family caregivers [24]. An Alzheimer's disease diagnosis often doesn't occur until the symptoms are advanced, and a person is in the later stages of dementia. It would be better if the diagnosis occurred much earlier, during the mild cognitive impairment (MCI) stage. Undiagnosed, misdiagnosed and unmanaged Alzheimer's disease can result in unnecessary suffering for the individual with the disease and their family. Moreover, the cost of care can be much more expensive than adequately managed Alzheimer's disease. Another benefit of an early diagnosis is that it gives the person with Alzheimer's disease the opportunity to participate in clinical trials and making their own life decisions. Medication can assist with specific symptoms, but clinical trials can match patients to studies focused on their condition, allowing them to participate in research that could alter the disease.</p>
<p>Though there is no cure for brain diseases like Alzheimer's, some medications and treatment plans can assist in making a big difference in daily functioning and disease development. We understand that we can preserve our health, including cognitive health, through positive lifestyle changes. Proactive lifestyles matter, and the earlier they are put into effect, the better. It is never too late to start. Even a person who has been currently diagnosed with Alzheimer's can maintain their functioning longer under a program of proactive interventions.</p>
<p>A cognitive screening test is a tool and not a guaranteed solution for a complex problem. However, screening tools serve a crucial role in documenting early signs of cognitive impairment. The tools may allow physicians to discover patterns in brain function decline before they've progressed into dementia. Often, these tools are meant to identify dementia itself so that people can understand what's happening to them and then make the best decision they can with that information. The next step is tracking down the cause of the cognitive decline, playing an active role in care coordination and investigating if medication and lifestyle changes may slow the disease progression. By engaging patients in their overall health conversations and focusing on how their overall health supports brain functioning, you can turn a scary discussion and possible realization into an opportunity for patient empowerment and better disease management.</p>
<p>Physicians play an essential role in identifying individuals at risk. Identifying and recommending various lifestyle changes for an adult in midlife may prevent or slow down the disease, and a timely diagnosis may be helpful and start a meaningful conversation with the patient [25]. Early diagnosis and intervention is an optimal strategy for patient care because the individual's level of functioning can be preserved for a longer period of time.</p>
<p>Benefits of early Alzheimer's disease diagnosis to the patient</p>
<p> Early diagnosis explains the signs, symptoms, and behavioral changes that the patients are experiencing. This diagnosis provides an answer for their suspicions.</p>
<p> An early diagnosis offers access to the right services and supports to help individuals take control of their condition and experience, live independently in their own home for longer and maintain a good quality of life for themselves, their family, and caregivers.</p>
<p> A good quality of life in the early stages of the disease can be maintained for several years.</p>
<p> Diagnosed individuals have the opportunity to plan ahead while they have the capacity to do so.</p>
<p> Individuals also have the opportunity to participate in their own legal, financial and future support/care options and treatment and make their wishes known to family members and the medical team.</p>
<p> It is only through receiving a diagnosis that patients can access treatments and support to improve their cognition and enhance their quality of life.</p>
<p> Early diagnosis offers caregivers the time to adjust to the changes in function, personality, mood and behaviors that come with the stages of the disease and their transition to the caregiver role, especially those who are spouses or adult children, where the roles change tremendously.</p>
<p> Caregivers who are prepared tend to adapt better, feel more competent to provide care, experience fewer psychological problems such as anxiety and depression and delay the institutionalization of their loved ones with Alzheimer's disease.</p>
<p>3.12.</p>
<p>Benefits of early screening for the physician Should the cognitive screening result be negative, concerns may be alleviated until later. Screening should be conducted annually to monitor changes from the baseline established from the initial assessment. If the screening result is positive, then further medical evaluation is required: The next step would be to identify the cause of the individual's cognitive changes (such as depression, delirium, urinary tract infection, thyroid imbalance, medication side effects, metabolic and endocrine imbalance, anxiety or Alzheimer's or another dementia) [26]. This may result in:</p>
<p> Treatment of the underlying disease or health conditions  Managing comorbidities effectively  Referring the person and their caregiver to a specialist in behavioral health. A specialist may be able to provide the individual with memory tools used to become more organized to manage their changing symptoms better</p>
<p> Addressing safety issues  Engaging the person to create or update their advance directives and long-term care  Ensuring the person has support through a care network, support and services  Assistance with medical, legal and financial matters  Ensuring the person and their caregiver receive the appropriate information, referrals, and other support for coping with Alzheimer's disease</p>
<p> Working with the individual and their care partner on developing care strategies to improve their quality of life, making necessary modifications to the person's lifestyle and home safety and managing emotional experiences related to the Alzheimer's diagnosis  Encouraging both the individual and caregiver to participate in clinical research  Ensuring that the caregiver receives the compassion and appropriate information, referrals, and support in coping with the Alzheimer's disease diagnosis and stress management</p>
<p>Cognitive screening test options</p>
<p>There are several widely known cognitive screening tests available. So, which cognitive screening tests are recommended for use in the Medicare Annual Wellness Visit? What circumstances require further testing? The Medicare Annual Wellness Visit does not recommend a preferred cognitive test. Whenever possible, it is best to use standardized, validated tools because they are required for some elements of the assessments. Not all tools have been formally tested for validity and uptake in actual primary care physician practices. Ideally, cognitive assessment tools should be:</p>
<p> Practical. Minimum time and effort to complete in the primary care setting. Ideally administered by a non-physician such as a medical assistant or nurse.</p>
<p> Retrievable. Searchable at point of care and included in any electronic health records.</p>
<p> Scorable. Results are illustrated in single numbers. Specific screening tests are often based on the physician's observations and the patient's responses. A cognitive screening test can be administered in less than 10 minutes and may reveal crucial data indicating the need for further testing. Patients who willingly confirm awareness of their symptoms or who have scores that indicate a possible memory problem on the initial screening test should be given a more detailed assessment and be referred for a complete cognitive evaluation. Patients who deny symptoms observed by clinicians or reported by family members or cannot confirm their symptoms should still be given a brief structured assessment, such as the MMSE, Mini-Cog, MIS, MOCA or GPCOG.</p>
<p>Importantly, collecting symptoms, which can be accomplished through tools such as the Short IQCODE or AD8, allows you to gather more insight, especially if they are administered concurrently. Collecting symptoms can help with monitoring responses to therapeutic interventions. The goal of collecting and assessing symptoms would be to gather data that is valid, reliable, responsive to change, discriminating and unbiased. Important considerations would be the method of data collection, which should be accessing the symptoms, the timing of the assessment and the methods used to assess multiple symptoms.</p>
<p>Patients may view the topic of cognitive decline as frightening, especially when they're speaking about a disease that has no actual treatment and no cure. On the other hand, physicians may see the topic of cognitive decline as a medical health discussion that seeks to track the change in the condition. When your patients' cognitive screening test scores justify further exploration, taking a proactive viewpoint in the exam room is essential. This can make all the difference to the patient. Physicians need to explain to their patients that a cognitive screening test is an assessment, not a diagnosis. While screening tests may suggest a problem with brain function, further testing will be required to confirm a problem exists and determine what is causing it.</p>
<p>As a physician, it is essential to engage patients in the process of learning about and navigating their medical challenges. The health care provider can facilitate an active role for the patient in their continuing wellness, including directing them to the use of specialists and reliable online resources to help them learn more. Engaging the patients to positively approach their medical challenges through education will empower the patients.</p>
<p>Trained medical professionals can use readily available screening tools. Only 10 minutes or less is required for the screening to assess the individual for cognitive impairment. Though we know that screening tools alone are insufficient and do not provide a diagnosis of Alzheimer's disease, they are the most critical first step to objectively determine if a cognitive change is present. Below are several possible tools to use (shortlist):</p>
<p> The National Institute on Aging (NIA) does not endorse specific screening tools. The choice you make for the screening tool depends on and can range from the setting you will screen in, demographics and language, the target audience, population age and the administrator's expertise in the screening tests. Cognitive assessments can be performed on any visit. However, it is now a required component of the Medicare Annual Wellness Visit. Coverage for annual wellness visits and follow-up visits for cognitive assessment and care plan service is extended to patients who have had Medicare Part B coverage for at least 12 months. (It is recommended that you contact the Medicare and Medicaid offices to request the billing code.) The staff must be adequately trained to administer these screening tools. Therefore, it may be best to have selected individuals adequately trained and available to administer the tests each and every time.  [27].</p>
<p>Mini-Cog: The Mini-Cog is a rapid Alzheimer's screening test that takes approximately 3-5 minutes to administer. It combines a 3-item recall with the clock-drawing test and can assist in determining whether a person has or does not have dementia. This test is widely used, and reports have been positive. This test, like the other tests, does not provide a diagnosis. There is still the requirement to conduct a thorough diagnostic work-up [28].</p>
<p>Memory Impairment Screen (MIS): The memory impairment screen (MIS) is a brief screening tool to assess memory. It is often used as a preliminary test with other screening tools to evaluate the cognition of someone who seems to display some possible impairment in their ability to think and recall [29]. of cultural learning and language diversity on assessing baseline cognitive functioning. This is a multicultural cognitive assessment scale. When administering the RUDAS, the respondent must be encouraged to communicate in the language with which they are most competent and comfortable [39].</p>
<p>3.14.</p>
<p>Barriers to cognitive testing 3.14.1. Stigma</p>
<p>Alzheimer's disease-related stigma is often associated with loss of identity and independence and incorrect assumptions about an individual's mental and physical functioning from the moment the individual has been diagnosed [40]. Stigma associated with Alzheimer's and related dementia creates a barrier to early detection, diagnosis, care and support. The stigma of Alzheimer's is also prevalent in the health care system, particularly among health care professionals, including physicians. Often, physicians are reluctant to diagnose Alzheimer's or dementia due to not knowing much about the disease, fear of giving a death sentence to the older adult, stigma, and judgment of the illness, not understanding how various cultures view aging or mental health and not knowing what the next step of the assessment should be after the testing.</p>
<p>Culture really matters</p>
<p>Health inequities cause significant challenges in the medical community, but health care professionals, including physicians, hold a powerful tool at their disposal: Cultural Competence. Social determinants of health, such as a person's living and working conditions and the quality of access to health care, aren't the same for everyone. Cultural competence in the medical field addresses the disparities that people of racially and culturally diverse backgrounds often experience. It is crucial to ensure that all individuals receive the care needed to live healthier lives. Cultural competence in health care services may improve communication and collaboration between the physician and patient, increase and improve patient satisfaction and enhance adherence, thereby improving medical outcomes and reducing health disparities [40]. This information on cultural competency for physicians aims to promote an active and united approach to multicultural health issues in the medical field and medical school training. Interventions focused on cultural competence can positively impact health professionals' knowledge, attitudes and skills, including patient satisfaction, understanding of the disease and increased likelihood of participating in preventative care and lifestyle modifications [40,41]. Cultural competence in health care means delivering effective, quality care to patients with diverse beliefs, attitudes, values and behaviors. This also requires an understanding of any potential impact that cultural differences can have on health care delivery.</p>
<p>3.14.3. What is cultural competence in health care?</p>
<p>Cultural competence in health care delivers practical and quality care to individuals of diverse backgrounds, beliefs, values and behaviors. This includes people from distinctive ethnic and racial groups, those from diverse socioeconomic backgrounds, people with disabilities and members of the LGBTQ+ communities [40,41]. The medical field must offer personalized care and support to these diverse individuals according to their cultural and linguistic differences. It also requires that physicians and other health care professionals understand the potential impact that cultural differences can have on their health care delivery to those different than themselves. For example, an individual's race, ethnicity, socio-cultural beliefs and traditions, socioeconomic status, health literacy, and some other factors can influence their care, including</p>
<p> The individual's perception of their symptoms and how it affects their health  How and when the individual seeks care  The individual's expectation of care they seek  The individual's choice and preference for care treatments  The individual's readiness to follow the physician's recommendations or treatment plans  Who the individual believes should be involved with making medical decisions for them 3.14.4. Improving cultural competence in health care</p>
<p>For the physician and their medical team to meet the needs of all patients, they must learn how to improve cultural competence in health care. They can then begin implementing strategies to develop and enhance cultural competence among their health care teams. Here are a few strategies to begin the process of removing the barriers to increasing cognitive assessments within diverse communities:</p>
<p> Promote awareness and education on the importance of cultural competency  Medical professionals need to identify their own beliefs and build an awareness of their own cultural biases and microaggressions</p>
<p> Be open to unfamiliar attitudes, practices, beliefs, biases, microaggressions and behaviors on both sides of the table (It can improve collaboration with patients and help them to respond with flexibility) 3.14.5. Benefits of cross-cultural awareness  Improved rapport  Person-centered recommendations and treatment plans  Improved patient participation and compliance</p>
<p>3.15.</p>
<p>Removing the barriers to screening</p>
<p>Communicating with an older adult</p>
<p>Good communication is an integral part of the healing process. Many patients may prefer direct responses to the changes they are experiencing, while some prefer a reserved and cautious approach [42]. With effective communication, physicians or other health care professionals can dramatically improve their skills of speaking with, assessing and establishing more satisfying relationships with their patients. Effective communication can also help prevent medical errors, improve health outcomes, make the most out of restricted interaction time and strengthen patient and caregiver relationships [43,44]. Here are a few tips for establishing your relationship with an older adult:</p>
<p> Establish respect immediately by using formal language (Such as using Mr., Mrs., Ms., Dr.), and then let them guide you about how they would like to be addressed after that or ask your patient how they would like to be addressed.</p>
<p> Be candid when speaking to an older adult about their cognitive decline or Alzheimer's disease. Truth-telling is an essential component but being respectful of the person's dignity and emotions is equally crucial. While it is necessary to be honest, avoid conflict that could lead to resistance. With resistance, you will get nowhere.</p>
<p> Introduce yourself clearly but not too quickly to both the patient and caregiver.</p>
<p> Speak slowly instead of speaking at a rapid-fire pace, as older adults may have difficulty following.</p>
<p> They need time to process information that is being asked or said.</p>
<p> It is okay to ask friendly questions about their families and activities, as this can relieve stress. Often this only takes 20-30 seconds, but it can go a long way in helping build rapport.</p>
<p> Ensure that your waiting area has comfortable seats for the older adults.</p>
<p> Inform staff of the importance of being mindful of the older adult patients who may need to be escorted to and from the offices, restroom, exam room and waiting area.</p>
<p> Staff should check on older adults often, especially if they have a long wait in the exam room.</p>
<p> Build rapport with both the patient and caregiver.</p>
<p> Show that you are interested in the patient and their concerns from the start. Even if the caregiver is there, direct your attention and questions to the patient first and then to the caregiver (i.e., address the patient directly, even if the caregiver is answering the questions). This engages the patient and makes it more likely that they answer the question in their own words.</p>
<p>Finding the time to screen</p>
<p>Make cognitive screening a part of your standard clinical protocol:</p>
<p> Provide standard education on cognitive changes as people age.</p>
<p> Become comfortable asking your patients about cognitive symptoms and ask every patient at some point in the year.</p>
<p> Screen for memory loss and change in thinking patterns for older adults by incorporating screening tools or questionnaires.</p>
<p> It is essential to screen because of inadequate detection due to a mismatch in the expectations between patients and their physicians.</p>
<p> Cognitive screenings should be a routine part of any primary care visit for older adults aged 65 and older.</p>
<p> Remember that culture does matter.</p>
<p>Disclosing the diagnosis</p>
<p>In a clinical practice setting, disclosure refers to the diagnosis of dementia and an explanation of the specific disease identified through the diagnostic evaluation as the most likely cause of dementia.</p>
<p> The diagnosis of Alzheimer's disease or related dementia is when the disorder most commonly causing dementia syndrome is disclosed to patients and caregivers.</p>
<p> Diagnosis is disclosed to patients and caregivers less than 50% of the time.</p>
<p> Withholding the diagnosis of dementia and its specific disease is a significant disadvantage to many patients and their families. Non-disclosure delays their access to available services and treatments to improve their cognition, assist them in planning for their future and enhance their quality of life.</p>
<p> Be honest and informative but watch for the patient's and family's responses. They may not be ready to hear all the information at once.</p>
<p>Medication list review</p>
<p>The field of medicine is not fixed. The medical field experiences constant changes, additions, reviews and recalls. A patient's conditions also change. Medication review is a necessary task in helping to prevent adverse reactions from medications, prevent adverse drug combination interactions, improve the patient's medical condition, remove ineffective medications and reduce the usage of medicines to save money. Reviewing   Emphasize medication reduction: A brown bag review may result in the physician stopping some medications, which is often appealing to patients</p>
<p> Provide a carrier: Consider providing your patients with a small bag (canvas, paper or plastic) to carry their medications. The bag may have a printed reminder on one side and your practice name on the other.</p>
<p>Set out the medications  The nurse should place all the patient's medications on the counter in the exam room to remind the clinician to perform a medication review.</p>
<p>Review the medications  Introduce the review process: Ask the patient if they have any questions about their medications and verbally acknowledge the purpose of reviewing medications.</p>
<p>Clarify medication instructions</p>
<p> Review what medications they should be taking now and how to handle them with the patient. Use the "teach-back method" to confirm understanding. behavior variant FTD, primary progressive aphasia and FTD with motor neuron disease. It is manifested with personality changes and deterioration of language skills. This rare form of dementia tends to occur in people younger than 60. Impairment is irreversible. Pick's disease is a type of frontotemporal dementia where one's brain cells gradually stop working, and those areas shrink.</p>
<p>Geriatric assessment. An evaluation of physical, physiological or mental functioning in the older adult population group. It is the complete examination of an older adult, which includes a total evaluation of their physical and cognitive conditions and a check of the patient's emotional state.</p>
<p>HIV-associated dementia. This rare disease is when the HIV virus spreads to the brain. Impairment is irreversible.</p>
<p>Huntington's disease (HD). An inherited, progressive brain disease. Impairment is irreversible. Lewy body dementia (DLB). This progressive form of dementia is characterized by abnormal amounts of protein deposits (alpha-synuclein) in the brain. These deposits of protein are called Lewy bodies. It occurs in the midbrain and cerebral cortex and causes loss of cholinergic and dopaminergic neurons. The signs and symptoms overlap with Alzheimer's and Parkinson's disease. Impairment is irreversible.</p>
<p>Mild cognitive impairment (MCI). MCI is when a person may experience more memory loss or thinking problems than the average person their age. The symptoms of MCI are not as severe as those of Alzheimer's disease or related dementia. Individuals with MCI are usually able to care for themselves and carry out their activities of daily living.</p>
<p>Mixed dementia. Mixed dementia is a condition in which a person has more than one type of dementia. Alzheimer's disease and vascular dementia is the most common type. Impairment is irreversible.</p>
<p>Parkinson's disease. It is a progressive degenerative disorder of the central nervous system. Due to nerve cell damage in the brain, dopamine levels drop, resulting in the symptoms of Parkinson's. Parkinson's disease is frequently accompanied by MCI and dementia, as the disease is progressive. Executive dysfunction will also develop. Cognitive changes experienced with Parkinson's are difficulty planning and accomplishing tasks and feelings of distraction and disorganization. Visualspatial function may be impaired, along with short-term memory. Parkinson's disease can also affect one's movement. Signs and symptoms include tremors which are often most noticeable during rest, muscle rigidity, slowing of voluntary movements, a tendency to fall back and a mask-like facial expression. Impairment is irreversible.</p>
<p>Reversible dementias. These conditions may be associated with cognitive or behavioral symptoms that can be resolved once the primary cause is treated. Vascular dementia. Vascular dementia is the second most common dementia in older adults. It is a degenerative condition. This dementia is used to describe problems with planning, judgment, reasoning, memory and thought processes caused by conditions that cause brain damage in the blood vessels in the brain or interrupt the flow of blood and oxygen to the brain. It leads to reduced brain activity. Impairment is irreversible.</p>
<p>Discussion</p>
<p>Efforts in the United States have been limited in scope when it comes to improving cognitive impairment care related to dementia in older adult Americans. There are many barriers within the healthcare systems and amongst the health care professionals that have yet to be addressed. The creation of a national strategy with mandated education for health care professionals will provide clinicians and other medical professionals with sustainable improvements, including knowledge and transferable skills for dementia detection, diagnosis and care. Best practice should include and embrace early detection and diagnosis. Currently, diagnosis occurs during the time of a family crisis.</p>
<p>Removing the barriers that could lead to social change in the medical field's response to early detection, diagnosis, disclosure and care will require mandated dementia education that is specific, detailed, consistent and substantial. We need to improve further education that surpasses the formal education that only touches on the pharmacology and pathophysiology in formal dementia education. Educational interventions require a broader scope that addresses the gaps related to clinician attitudes, knowledge, skills, and behaviors.</p>
<p>It is important for the creation and dissemination of new knowledge using revised or modernized cognitive assessment tools. These assessment tools should consider the many factors in aging, such as age, education, culture, race, sexual identity, language, attitude, beliefs about the symptoms of dementia, vision and hearing impairment and illiteracy or lower education levels. At this time, it is now critical to have effective and efficient transferal of gained knowledge to clinician practices and interventions that are tangible, substantial, and sustainable. Without the acknowledgement and action based on clinical recommendations on dementia education, Alzheimer's disease and related dementias will become more of an uncontainable problem, with increased under-detection, misdiagnosis and untreated illnesses contributing to the escalation of other health and financial issues.</p>
<p>Implications for advanced clinician knowledge and practice</p>
<p>This article addressed the current and ever-growing challenges faced by primary care physicians and other clinicians regarding the current dementia care knowledge and attitudes that exist in the medical field. There is an urgent and critical need for removing the barriers to dementia early detection, diagnosis and care. In the article "The Knowledge and Attitudes of Primary Care and the Barriers to Early Detection and Diagnosis of Alzheimer's Disease," the author summarized the need to improve and increase the training for physicians, medical students, and other medical staff. Training needs to be accessible to all professionals working with the older adult population. The article also discussed the need for the implementation of national or statewide dementia educational programs that enhance the skills of clinicians. Because the medical field is not static, from medical school to clinical practice, dementia education should be ongoing. This action will ensure that there is long-term sustainability in dementia care and dementia education programs.</p>
<p>Limitations</p>
<p>One of the limitations of this article is that it is in the form of an informative and actionable toolkit. It is very specific to primary care physicians and other clinicians. Though other medical staff and other health care professionals would benefit from this information, they were not included. However, they would greatly benefit from the newly generated knowledge in dementia care, as it would enhance their knowledge and care practices.</p>
<p>Recommendations</p>
<p>Cognitive impairment is a medical condition. It is imperative to acknowledge, understand and act, as cognitive impairments, whether reversible or irreversible, require the attention of clinicians and others in the health care community. The Medicare Annual Wellness Visit (AWV) was implemented to include cognitive assessments since cognitive impairments, AD and other dementias have been underdetected and under-diagnosed. The 2019 Alzheimer's Association Report states that approximately only 50 percent of patients use their primary care physician to assess their cognitive functioning. The intention of this article is to broaden the knowledge of the barriers to early detection, diagnosis and care within the medical field so that primary care physicians and other clinicians can use it to understand and improve their cognitive screening knowledge, accuracy and confidence and advocate for more valuable and equitable dementia care education to care for the diverse population of older adults. Education of removing the barriers to detection and diagnosis of cognitive impairments and understanding the diseases, causes and stages in older adults should be requirements for medical professionals. Cognitive assessments should be a standard protocol for primary care professionals caring for older adults.</p>
<p>Conclusions</p>
<p>This toolkit can act as an educational intervention in primary care practices to improve the rates of, accuracy of and access to cognitive assessments for brain health decline. Reducing the barriers to early detection and diagnosis will lead to accurate care and reduce the gaps in detection. This toolkit is an introduction to reducing the prevalent gaps, and more work is required to overcome barriers to the development and implementation of educational interventions that increase feasibility in medical practices.</p>
<p>Figure 1 .
1Main challenges encountered in clinical practices that overlap.</p>
<p>MMSE-Mini Mental State Examination (MMSE)  Mini-Cog-Mini Cognition  MIS-Memory Impairment Screen  MOCA-Montreal Cognitive Assessment  SLUMS-the Saint Louis University Mental Status Examination  GPCOG-General Practitioner assessment of Cognition  AD8-AD8 Informant Interview  The Clock Drawing Test for Alzheimer's  Short IQCODE-Short Form of the Questionnaire on Cognitive Decline in the Elderly  RUDAS-Rowland Universal Dementia Assessment Scale</p>
<p>3.1.7. Signs and symptoms of Alzheimer's diseaseAlthough each individual is unique, experts have identified common warning signs of Alzheimer's disease, including Memory loss, especially of recent events, names, places and other new informationThe most popular of AD stages set by the National Institutes of Health's National Institute on Aging describes the disease in three stages: early (mild), middle (moderate) and late (severe).3.2.1. Early (Mild)In this stage, people may  Forget words or misplace objects  Forget something they just read  Ask the same question over and over  Have increasing trouble making plans or organizing  Not remember names when meeting new people3.2.2. Middle (Moderate)In this stage, people may have  Increased memory loss and confusion  Problems recognizing family and friends  Continuous repeating of stories and questions, favorite wants (e.g., foods, places, songs etc.), or motions Confusion about time and place 
 Struggling to complete familiar and complex tasks such as managing medications, managing 
finances, driving or household chores 
 Trouble finding appropriate words, for example, in a sentence 
 Difficulties in judging situations 
 Changes in mood and personality </p>
<p>3.2. Stages of Alzheimer's disease </p>
<p>in the family history  Depression  Brain injury  Strokes  Lack of exercise  Diabetes  Obesity  Poor diet, which refers to the failure to provide the body with adequate amounts of and forms of nutrients for ultimate healthThe most common causes of dementia are as follows. Cardiovascular disease 
 Sleep apnea 
 Smoking and heavy alcohol use 
 Infection of the brain (such as syphilis and meningitis) </p>
<p>3.4. Common causes of dementia </p>
<p>3.4.1. Degenerative neurological diseases </p>
<p> Alzheimer's disease 
 Dementia with Lewy Bodies 
 Huntington's disease 
 Parkinson's disease 
 Some forms of multiple sclerosis </p>
<p>3.4.2. Vascular disorders </p>
<p> Stroke, aneurysmal SAH or cerebral amyloid angiopathy 
3.4.3. Other common causes of dementia include </p>
<p> HIV/AIDS-associated neurocognitive disorders (HAND) 
 Chronic alcoholism 
 Tumors 
 Vitamin B12 deficiency 
 Carbon monoxide poisoning 
 Cerebral anoxia 
 Hypothyroidism 
 Subdural hematoma 
 Hypothyroidism, hypoglycemia </p>
<p>Table 1 .
1Common causes of cognitive impairment, 2022.</p>
<p>Table 2 .
2Neurodegenerative conditions -Progressive dementias.Condition 
Warning signs 
Alzheimer's disease 
Increased memory loss, confusion, inability to learn new information, 
difficulty with language, reading and writing and decline in judgment. 
Parkinson's disease 
Tremors/shaking of limb, hand or fingers. Rigid muscles, impaired 
posture and balance, loss of automatic movements and speech and 
writing changes. 
Lewy body dementia 
Hallucinations or delusions, changes in movement, sleep problems, 
behavior shifts. 
Frontotemporal disease 
Apathy, unwillingness to talk, personality/mood changes, depression, 
lack of inhibition, lack of social tact, obsessive/repetitive behaviors. 
Vascular dementia </p>
<p>Table 3 .
3Reversible dementias.Referred to as "water on the brain." -a condition where extra spinal fluid gets trapped in the brain.Reversible dementia 
Causes 
Symptoms 
Normal pressure 
Hydrocephalus </p>
<p>Confusion &amp; memory loss, 
urinary incontinence, balance 
and walking problems. 
Nutritional 
Deficiencies/Vitamin B12 
deficiency </p>
<p>Poor diets, other health problems such as 
pernicious anemia or Crohn's disease and 
older age cause reduced ability to absorb 
this vitamin. </p>
<p>Similar to Alzheimer's disease -
memory loss, behavior changes, 
agitation. </p>
<p>Thiamine/ 
Wernicke/Korsakoff 
syndrome </p>
<p>Thiamine deficiency (Vitamin B1). It is 
often due to alcohol abuse. </p>
<p>Ataxia, muscle weakness, 
diminished/hyperactive 
reflexes, urinary or fecal 
incontinence, loss of vision. 
Thyroid disorders 
Hypothyroidism and hyperthyroidism. 
Memory loss, difficulty finding 
the right word, concentrating, 
poor spatial organization and 
slower visual processing. 
Sleep deficits 
Chronic sleep deprivation causes memory 
and overall cognition to decline. </p>
<p>Significant impact on the ability 
to think or reason. 
Brain lesions 
Risk factors: radiation exposure, age, 
obesity, pesticide exposure and genetic 
factors. </p>
<p>Memory loss, poor judgment, 
personality changes, impulse 
control, headaches, seizures and 
hearing. Vision, speech and 
physical changes. 
Delirium 
Urinary Tract infection or pneumonia. 
Increase in challenging 
behaviors, more lethargy, 
increased confusion 
Subdural hematomas 
It can develop from what is a minor bump 
on the head. </p>
<p>Confusion, lethargy, difficulty 
with speech and headaches 
Depression/Mood changes 
-
Symptoms are similar to early 
signs of dementia, memory loss 
and problems with word recall. 
Medication reactions 
Some medications cause cognitive issues: 
Cholesterol-lowering statins, 
Chemotherapy rugs, Pain medications, 
Anti-Anxiety medications and Sleeping 
pills. 
Alcohol/Tobacco/Drug use Cause of type of anemia. 
Iron Deficiency 
Dehydration 
A person's awareness of thirst declines 
with age. 
Anoxia/Hypoxia 
A state of oxygen deprivation. Caused by 
a heart attack, monoxide poisoning or 
severe asthma. 
Withdrawal from drugs 
Discontinuing use of some prescriptions. 
Confusion and disorientation. </p>
<p>3.13.1. Who can use these tests? Physicians (Primary Care Physicians or Specialist Physicians) and more 3.13.2. Most popular cognitive tests MMSE: The Mini-Mental State Examination (MMSE) is a widely used and reliable tool for detecting dementia. Taking about 10 minutes to complete, the MMSE measures various aspects of cognition, including language abilities, orientation, word recall, attention and calculation, language abilities and visual construction. MMSE is managed by Psychological Assessment Resources (PAR). You are required to register, complete a four-page permissions request form and pay a fee for each MMSE form and its use (approximately $1.35). Scores may need to be adjusted or interpreted differently to account for a person's age, educational level and ethnicity/race Nurses 
 Speech-Language Pathologists 
 Occupational Therapists 
 Nurse practitioners 
 Physician assistants 
 Neurologists 
 Psychologists 
 Geriatricians 
 </p>
<p>and discussing medications with your patient may help you to medications and over-the-counter supplements. Conducting the brown bag review can be an eye-opening experience for many physician offices. Here are a few tips to get patients to bring all medications and supplements:What to bring: Review with patients what to bring  All prescription medicines (including pills, drops, inhalers and creams)  All over-the-counter medicines and supplements they take regularly  All vitamins and supplements  All herbal medicines Ways to remind  On the appointment card  During the appointment reminder call  During the visit: discuss as a part of their visit  Hang posters in the exam rooms and the waiting room  Bulletin board: Display a bulletin board with anonymous case studies and persuasive reasons for bringing in their medications Respond to the patient's questions 
 Verify their medications 
 Identify medication interactions and medication errors </p>
<p>3.16.1. Action: Do a brown bag check </p>
<p>A brown bag check is critical to the care of your patient. Ask your patient to bring to their 
appointment all 
 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0).
Conflict of interestThe authors declare no conflict of interest.
15(a) Detection of any cognitive impairment. 15#p-410.15Code of Federal Regulations (2022) Title 42 CFR 410. Detection%20of%20any%20cognitive%20impairment)Code of Federal Regulations (2022) Title 42 CFR 410.15(a) Detection of any cognitive impairment. Available from: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-410/subpart- B/section-410.15#p-410.15(a)(Detection%20of%20any%20cognitive%20impairment).</p>
<p>Alzheimer's Foundation of America (AFA) (2022) What is a memory screening. Alzheimer's Foundation of America (AFA) (2022) What is a memory screening? Available from: https://alzfdn.org/memory-screening/what-is-memory-screening/.</p>
<p>Centers for Disease Control and Prevention (CDC) (2022) What is dementia. Centers for Disease Control and Prevention (CDC) (2022) What is dementia. Available from: https://www.cdc.gov/aging/dementia/index.html.</p>
<p>The characterization of subjective cognitive decline. F Jessen, R Amariglio, R Buckley, 10.1016/S1474-4422(19)30368-0Lancet Neurol. 19Jessen F, Amariglio R, Buckley R, et al. (2020) The characterization of subjective cognitive decline. Lancet Neurol 19: 271-278. https://doi.org/10.1016/S1474-4422(19)30368-0</p>
<p>Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. N C Cullen, A Leuzy, S Palmqvist, 10.1038/s43587-020-00003-5Nat Aging. 1Cullen NC, Leuzy A, Palmqvist S, et al (2021) Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging 1: 114-123. https://doi.org/10.1038/s43587-020-00003-5</p>
<p>A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. F Jessen, R E Amariglio, M Van Boxtel, 10.1016/j.jalz.2014.01.001Alzheimers Dement. 10Jessen F, Amariglio RE, van Boxtel M, et al. (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 10: 844-852. https://doi.org/10.1016/j.jalz.2014.01.001</p>
<p>Diagnosis and treatment for mild cognitive impairment: A systematic review of clinical practice guidelines and consensus statements. Y X Chen, N Liang, X L Li, 10.3389/fneur.2021.719849Front Neurol. 12719849Chen YX, Liang N, Li XL, et al. (2021) Diagnosis and treatment for mild cognitive impairment: A systematic review of clinical practice guidelines and consensus statements. Front Neurol 12: 719849. https://doi.org/10.3389/fneur.2021.719849</p>
<p>Alzheimer's Disease Fact Sheet. 20National Institute of AgingNational Institute of Aging (2022) Alzheimer's Disease Fact Sheet. Available from: https://www.nia.nih.gov/health/alzheimers-disease-fact- sheet#:~:text=Estimates%20vary%2C%20but%20experts%20suggest,of%20dementia%20amon g%20older%20adults.</p>
<p>Dementia prevention, intervention, and care. G Livingston, A Sommerlad, V Orgeta, 10.1016/S0140-6736Lancet. 39017Livingston G, Sommerlad A, Orgeta V, et al. (2017) Dementia prevention, intervention, and care. Lancet 390: 2673-2734. https://doi.org/10.1016/S0140-6736(17)31363-6</p>
<p>Alzheimer's Association. 2022Alzheimer's Association (2022) 2022</p>
<p>Alzheimer's disease facts and figures. 10.1002/alz.12638Alzheimers Dement. 18Alzheimer's disease facts and figures. Alzheimers Dement 18: 700-789. https://doi.org/10.1002/alz.12638</p>
<p>Depression-an underrecognized target for prevention of dementia in Alzheimer's disease. F S Dafsari, F Jessen, 10.1038/s41398-020-0839-1Transl Psychiatry. 10Dafsari FS, Jessen F (2020) Depression-an underrecognized target for prevention of dementia in Alzheimer's disease. Transl Psychiatry 10: 1-13. https://doi.org/10.1038/s41398-020-0839-1</p>
<p>A review of barriers and enablers to diagnosis and management of persons with dementia in primary care. F Aminzadeh, F J Molnar, W B Dalziel, 10.5770/cgj.15.42Can Geriatr J. 15Aminzadeh F, Molnar FJ, Dalziel WB, et al. (2012) A review of barriers and enablers to diagnosis and management of persons with dementia in primary care. Can Geriatr J 15: 85-94. https://doi.org/10.5770/cgj.15.42</p>
<p>Early diagnosis of dementia in the primary care setting. Dsc Chai, Singapore Fam Physician. 39Chai DSC (2013) Early diagnosis of dementia in the primary care setting. Singapore Fam Physician 39: 15-18.</p>
<p>Digital Cognitive Assessments for Dementia: Digital assessments may enhance the efficiency of evaluations in neurology and other clinics. A M Staffaroni, E Tsoy, J Taylor, Pract Neurol. 202024Staffaroni AM, Tsoy E, Taylor J, et al. (2020) Digital Cognitive Assessments for Dementia: Digital assessments may enhance the efficiency of evaluations in neurology and other clinics. Pract Neurol 2020: 24.</p>
<p>Global perspectives on brief cognitive assessments for dementia diagnosis. E Tsoy, A B Sideman, Pia Escudero, S D , J Alzheimers Dis. 82Tsoy E, Sideman AB, Pia Escudero SD, et al. (2021) Global perspectives on brief cognitive assessments for dementia diagnosis. J Alzheimers Dis 82: 1001-1013.</p>
<p>. 10.3233/JAD-201403https://doi.org/10.3233/JAD-201403</p>
<p>Physician perceptions about the barriers to prompt diagnosis of mild cognitive impairment and Alzheimer's disease. D Judge, J Roberts, R Khandker, 10.1155/2019/3637954Int J Alzheimers Dis. Judge D, Roberts J, Khandker R, et al. (2019) Physician perceptions about the barriers to prompt diagnosis of mild cognitive impairment and Alzheimer's disease. Int J Alzheimers Dis. https://doi.org/10.1155/2019/3637954</p>
<p>Timely diagnosis for Alzheimer's disease: A literature review on benefits and challenges. B Dubois, A Padovani, P Scheltens, 10.3233/JAD-150692J Alzheimers Dis. 49Dubois B, Padovani A, Scheltens P, et al. (2016) Timely diagnosis for Alzheimer's disease: A literature review on benefits and challenges. J Alzheimers Dis 49: 617-631. https://doi.org/10.3233/JAD-150692</p>
<p>The knowledge and attitudes of primary care and the barriers to early detection and diagnosis of Alzheimer's disease. 10.3390/medicina58070906Medicina. de Levante Raphael D58906de Levante Raphael D (2022) The knowledge and attitudes of primary care and the barriers to early detection and diagnosis of Alzheimer's disease. Medicina 58: 906. https://doi.org/10.3390/medicina58070906</p>
<p>Primary care physicians' perceived barriers to optimal dementia care: a systematic review. E Mansfield, N Noble, R Sanson-Fisher, 10.1093/geront/gny067Gerontologist. 59Mansfield E, Noble N, Sanson-Fisher R, et al. (2019) Primary care physicians' perceived barriers to optimal dementia care: a systematic review. Gerontologist 59: e697-e708. https://doi.org/10.1093/geront/gny067</p>
<p>Methods and approaches for enhancing communication with people with moderate-to-severe dementia that can facilitate their inclusion in research and service evaluation: Findings from the IDEAL programme. R Collins, A Hunt, C Quinn, 10.1177/14713012211069449Dementia. 21Collins R, Hunt A, Quinn C, et al. (2022) Methods and approaches for enhancing communication with people with moderate-to-severe dementia that can facilitate their inclusion in research and service evaluation: Findings from the IDEAL programme. Dementia 21: 1135-1153. https://doi.org/10.1177/14713012211069449</p>
<p>Communication in healthcare interactions in dementia: a systematic review of observational studies. J Dooley, C Bailey, R Mccabe, 10.1017/S1041610214002890Int Psychogeriatr. 27Dooley J, Bailey C, McCabe R (2015) Communication in healthcare interactions in dementia: a systematic review of observational studies. Int Psychogeriatr 27: 1277-1300. https://doi:10.1017/S1041610214002890</p>
<p>Screening for Cognitive Impairment in older adults: Recommendation statement. American Family Physician. Am Fam PhysicianAmerican Family Physician (2020) Screening for Cognitive Impairment in older adults: Recommendation statement. Am Fam Physician.</p>
<p>Stigmas of Alzheimer's disease and help seeking for Alzheimer's disease among African Americans. de Levante Raphael DWalden University ProQuest Dissertation Publishingde Levante Raphael D (2022) Stigmas of Alzheimer's disease and help seeking for Alzheimer's disease among African Americans. Walden University ProQuest Dissertation Publishing. Available from: https://www.proquest.com/openview/802dc2def82170fbb123ee9b4d89ea93/1?pq- origsite=gscholar&amp;cbl=18750&amp;diss=y.</p>
<p>Current and Future Treatments in Alzheimer Disease: An Update. K G Yiannopoulou, S G Papageorgiou, 10.1177/1179573520907397J Cent Nerv Syst Dis. 121179573520907397Yiannopoulou KG, Papageorgiou SG (2020) Current and Future Treatments in Alzheimer Disease: An Update. J Cent Nerv Syst Dis 12: 1179573520907397. https://doi.org/10.1177/1179573520907397</p>
<p>Long term course and effectiveness of combination therapy in Alzheimer's disease. A Atri, L Shaughnessy, J Locascio, 10.1097/WAD.0b013e31816653bcAlzheimer Dis Assoc Discord. 22Atri A, Shaughnessy L, Locascio J, et al. (2008) Long term course and effectiveness of combination therapy in Alzheimer's disease. Alzheimer Dis Assoc Discord 22: 209-221. https://doi:10.1097/WAD.0b013e31816653bc</p>
<p>Diagnosis of early Alzheimer's disease: Clinical practice in 2021. A P Porsteinsson, R S Isaacson, M N Sabbagh, 10.14283/jpad.2021.23J Prev Alzheim. 8Porsteinsson AP, Isaacson RS, Sabbagh MN, et al. (2021) Diagnosis of early Alzheimer's disease: Clinical practice in 2021. J Prev Alzheim 8: 371-386. https://doi.org/10.14283/jpad.2021.23</p>
<p>The mini-mental state examination (MMSE) from a language perspective: an analysis of test interaction. K Myrberg, L C Hydn, C Samuelsson, 10.1080/02699206.2019.1687757Clin Linguist Phonet. 34Myrberg K, Hydn LC, Samuelsson C (2019) The mini-mental state examination (MMSE) from a language perspective: an analysis of test interaction. Clin Linguist Phonet 34: 652-670. https://doi.org/10.1080/02699206.2019.1687757</p>
<p>Quick screening for early dementia detection. Mini-Cog, Mini-Cog. Quick screening for early dementia detection. Available from: https://dementiacare.com.my/abc-of-dementia/quick-screening-test-for-dementia/.</p>
<p>Screening for dementia with the memory impairment screen. H Buschke, G Kuslansky, M Katz, Neurology. 52231Buschke H, Kuslansky G, Katz M, et al. (1999) Screening for dementia with the memory impairment screen. Neurology 52: 231.</p>
<p>Validity of MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. S Hoops, S Nazem, A D Siderowf, Neurology. 73Hoops S, Nazem S, Siderowf AD, et al. (2009) Validity of MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73: 1738-1745.</p>
<p>. 10.1212/WNL.0b013e3181c34b47https://doi.org/10.1212/WNL.0b013e3181c34b47</p>
<p>Designing a Brief Alzheimer Screen (BAS). M Mendiondo, J W Ashford, F Schmitt, 10.3233/JAD-2003-5506J Alzheimers Dis. 5Mendiondo M, Ashford JW, Schmitt F, et al. (2003) Designing a Brief Alzheimer Screen (BAS). J Alzheimers Dis 5: 391-398. https://doi.org/10.3233/JAD-2003-5506</p>
<p>. General Practitioner Assessment of Cognition. General Practitioner Assessment of Cognition (2022) Available from: http://gpcog.com.au/.</p>
<p>Cognitive screening test in primary care: Cut points for low education. J E Yokomizo, K Seeher, G M De Oliveira, 10.11606/S1518-8787.2018052000462Rev Saude Publica. 5288Yokomizo JE, Seeher K, de Oliveira GM, et al. (2018) Cognitive screening test in primary care: Cut points for low education. Rev Saude Publica 52: 88. https://doi.org/10.11606/S1518- 8787.2018052000462</p>
<p>The AD8: The Washington University Dementia Screening Test. J Galvin, Y Zweig, Galvin J, Zweig Y (2021) The AD8: The Washington University Dementia Screening Test. Available from: https://hign.org/consultgeri/try-this-series/ad8-washington-university-dementia- screening test.</p>
<p>Usefulness of the clock drawing test as a cognitive screening instrument for mild cognitive impairment and mild dementia: an evaluation using three scoring systems. S Kim, S Jahng, K H Yu, 10.12779/dnd.2018.17.3.100Dement Neurocogn Disord. 17Kim S, Jahng S, Yu KH, et al. (2018) Usefulness of the clock drawing test as a cognitive screening instrument for mild cognitive impairment and mild dementia: an evaluation using three scoring systems. Dement Neurocogn Disord 17: 100-109. https://doi.org/10.12779/dnd.2018.17.3.100</p>
<p>Informant questionnaire on cognitive decline in the elderly (IQCODE) for assessing the severity of dementia in patients with Alzheimer's disease. Y Ding, J Niu, Y Zhang, 10.1186/s12877-018-0837-9BMC Geriatrics. 18146Ding Y, Niu J, Zhang Y, et al. (2018) Informant questionnaire on cognitive decline in the elderly (IQCODE) for assessing the severity of dementia in patients with Alzheimer's disease. BMC Geriatrics 18: 146. https://doi.org/10.1186/s12877-018-0837-9</p>
<p>. Dementia Australia, Rowland Universal Dementia Assessment Scale (RUDASDementia Australia, Rowland Universal Dementia Assessment Scale (RUDAS). Available from: https://www.dementia.org.au/resources/rowland-universal-dementia-assessment-scale-rudas.</p>
<p>Cultural competence in family practice and Primary care setting. R Kumar, S Bhattacharya, N Sharma, J Family Med Prim Care. 8Kumar R, Bhattacharya S, Sharma N, et al. (2019) Cultural competence in family practice and Primary care setting. J Family Med Prim Care 8: 11-14.</p>
<p>. 10.4103/jfmpc.jfmpc_393_18https://doi.org/10.4103/jfmpc.jfmpc_393_18</p>
<p>Practicing cultural competence and cultural humility in the care of diverse patients. D Stubble, 10.1176/appi.focus.20190041Focus. 18Stubble D (2020) Practicing cultural competence and cultural humility in the care of diverse patients. Focus 18: 49-51. https://doi.org/10.1176/appi.focus.20190041</p>
<p>Attitudes toward the diagnosis and disclosure of dementia among family caregivers and primary care physicians. C M Connel, L Boise, J C Stuckey, 10.1093/geront/44.4.500Gerontologist. 44Connel CM, Boise L, Stuckey JC, et al. (2004) Attitudes toward the diagnosis and disclosure of dementia among family caregivers and primary care physicians. Gerontologist 44: 500-507. https://doi.org/10.1093/geront/44.4.500</p>
<p>Improving communications with patients and families in geriatric care. The how, when and what. S C Huang, A Morgan, V Peck, 10.1177/23743735211034047J Patient Experience. 823743735211034047Huang SC, Morgan A, Peck V, et al. (2021) Improving communications with patients and families in geriatric care. The how, when and what. J Patient Experience 8: 23743735211034047. https://doi.org/10.1177/23743735211034047</p>
<p>Alzheimer's Association report shows significant disconnect between seniors, physicians when it comes to cognitive assessment. Alzheimer's Association (2019) NewAlzheimer's Association (2019) New Alzheimer's Association report shows significant disconnect between seniors, physicians when it comes to cognitive assessment. Available from: https://www.alz.org/news/2019/new-alzheimer-s-association-report-shows-signifi.</p>            </div>
        </div>

    </div>
</body>
</html>